Error while loading conda entry point: anaconda-anon-usage-plugin (No module named 'anaconda_anon_usage')
Error while loading conda entry point: anaconda-anon-usage-plugin (No module named 'anaconda_anon_usage')
# packages in environment at /cluster/home/gcardenal/miniconda3/envs/vllm_2:
#
# Name                    Version                   Build  Channel
_libgcc_mutex             0.1                        main  
_openmp_mutex             5.1                       1_gnu  
accelerate                1.1.1                    pypi_0    pypi
aiohappyeyeballs          2.4.0                    pypi_0    pypi
aiohttp                   3.10.6                   pypi_0    pypi
aiosignal                 1.3.1                    pypi_0    pypi
annotated-types           0.7.0                    pypi_0    pypi
anthropic                 0.40.0                   pypi_0    pypi
anyio                     4.6.0                    pypi_0    pypi
argon2-cffi               23.1.0                   pypi_0    pypi
argon2-cffi-bindings      21.2.0                   pypi_0    pypi
arrow                     1.3.0                    pypi_0    pypi
asttokens                 3.0.0                    pypi_0    pypi
async-lru                 2.0.4                    pypi_0    pypi
async-timeout             4.0.3                    pypi_0    pypi
attrs                     24.2.0                   pypi_0    pypi
babel                     2.17.0                   pypi_0    pypi
beautifulsoup4            4.12.3                   pypi_0    pypi
bleach                    6.2.0                    pypi_0    pypi
bzip2                     1.0.8                h5eee18b_6  
ca-certificates           2025.2.25            h06a4308_0  
certifi                   2024.8.30                pypi_0    pypi
cffi                      1.17.1                   pypi_0    pypi
charset-normalizer        3.3.2                    pypi_0    pypi
click                     8.1.7                    pypi_0    pypi
cloudpickle               3.0.0                    pypi_0    pypi
comm                      0.2.2                    pypi_0    pypi
datasets                  3.0.1                    pypi_0    pypi
debugpy                   1.8.14                   pypi_0    pypi
decorator                 5.2.1                    pypi_0    pypi
defusedxml                0.7.1                    pypi_0    pypi
dill                      0.3.8                    pypi_0    pypi
diskcache                 5.6.3                    pypi_0    pypi
distro                    1.9.0                    pypi_0    pypi
einops                    0.8.0                    pypi_0    pypi
emoji                     2.14.0                   pypi_0    pypi
exceptiongroup            1.3.0                    pypi_0    pypi
executing                 2.2.0                    pypi_0    pypi
fastapi                   0.115.0                  pypi_0    pypi
fastjsonschema            2.21.1                   pypi_0    pypi
filelock                  3.16.1                   pypi_0    pypi
fqdn                      1.5.1                    pypi_0    pypi
frozenlist                1.6.0                    pypi_0    pypi
fsspec                    2024.6.1                 pypi_0    pypi
gguf                      0.10.0                   pypi_0    pypi
h11                       0.16.0                   pypi_0    pypi
hf-xet                    1.1.2                    pypi_0    pypi
httpcore                  1.0.9                    pypi_0    pypi
httptools                 0.6.4                    pypi_0    pypi
httpx                     0.28.1                   pypi_0    pypi
huggingface-hub           0.32.3                   pypi_0    pypi
idna                      3.10                     pypi_0    pypi
importlib-metadata        8.7.0                    pypi_0    pypi
interegular               0.3.3                    pypi_0    pypi
ipykernel                 6.29.5                   pypi_0    pypi
ipython                   8.30.0                   pypi_0    pypi
ipywidgets                8.1.5                    pypi_0    pypi
isoduration               20.11.0                  pypi_0    pypi
jedi                      0.19.2                   pypi_0    pypi
jinja2                    3.1.4                    pypi_0    pypi
jiter                     0.10.0                   pypi_0    pypi
json5                     0.12.0                   pypi_0    pypi
jsonpointer               3.0.0                    pypi_0    pypi
jsonschema                4.24.0                   pypi_0    pypi
jsonschema-specifications 2025.4.1                 pypi_0    pypi
jupyter                   1.1.1                    pypi_0    pypi
jupyter-client            8.6.3                    pypi_0    pypi
jupyter-console           6.6.3                    pypi_0    pypi
jupyter-core              5.8.1                    pypi_0    pypi
jupyter-events            0.12.0                   pypi_0    pypi
jupyter-lsp               2.2.5                    pypi_0    pypi
jupyter-server            2.16.0                   pypi_0    pypi
jupyter-server-terminals  0.5.3                    pypi_0    pypi
jupyterlab                4.3.2                    pypi_0    pypi
jupyterlab-pygments       0.3.0                    pypi_0    pypi
jupyterlab-server         2.27.3                   pypi_0    pypi
jupyterlab-widgets        3.0.15                   pypi_0    pypi
lark                      1.2.2                    pypi_0    pypi
ld_impl_linux-64          2.40                 h12ee557_0  
libffi                    3.4.4                h6a678d5_1  
libgcc-ng                 11.2.0               h1234567_1  
libgomp                   11.2.0               h1234567_1  
libstdcxx-ng              11.2.0               h1234567_1  
libuuid                   1.41.5               h5eee18b_0  
llvmlite                  0.43.0                   pypi_0    pypi
lm-format-enforcer        0.10.6                   pypi_0    pypi
markupsafe                3.0.2                    pypi_0    pypi
matplotlib-inline         0.1.7                    pypi_0    pypi
mistral-common            1.4.3                    pypi_0    pypi
mistune                   3.1.3                    pypi_0    pypi
mpmath                    1.3.0                    pypi_0    pypi
msgpack                   1.1.0                    pypi_0    pypi
msgspec                   0.19.0                   pypi_0    pypi
multidict                 6.4.4                    pypi_0    pypi
multiprocess              0.70.16                  pypi_0    pypi
nbclient                  0.10.2                   pypi_0    pypi
nbconvert                 7.16.4                   pypi_0    pypi
nbformat                  5.10.4                   pypi_0    pypi
ncurses                   6.4                  h6a678d5_0  
nest-asyncio              1.6.0                    pypi_0    pypi
networkx                  3.3                      pypi_0    pypi
notebook                  7.3.1                    pypi_0    pypi
notebook-shim             0.2.4                    pypi_0    pypi
numba                     0.60.0                   pypi_0    pypi
numpy                     1.26.4                   pypi_0    pypi
nvidia-cublas-cu12        12.1.3.1                 pypi_0    pypi
nvidia-cuda-cupti-cu12    12.1.105                 pypi_0    pypi
nvidia-cuda-nvrtc-cu12    12.1.105                 pypi_0    pypi
nvidia-cuda-runtime-cu12  12.1.105                 pypi_0    pypi
nvidia-cudnn-cu12         9.1.0.70                 pypi_0    pypi
nvidia-cufft-cu12         11.0.2.54                pypi_0    pypi
nvidia-curand-cu12        10.3.2.106               pypi_0    pypi
nvidia-cusolver-cu12      11.4.5.107               pypi_0    pypi
nvidia-cusparse-cu12      12.1.0.106               pypi_0    pypi
nvidia-ml-py              12.575.51                pypi_0    pypi
nvidia-nccl-cu12          2.21.5                   pypi_0    pypi
nvidia-nvjitlink-cu12     12.9.41                  pypi_0    pypi
nvidia-nvtx-cu12          12.1.105                 pypi_0    pypi
openai                    1.48.0                   pypi_0    pypi
openssl                   3.0.16               h5eee18b_0  
outlines                  0.0.46                   pypi_0    pypi
overrides                 7.7.0                    pypi_0    pypi
packaging                 25.0                     pypi_0    pypi
pandas                    2.2.3                    pypi_0    pypi
pandocfilters             1.5.1                    pypi_0    pypi
parso                     0.8.4                    pypi_0    pypi
partial-json-parser       0.2.1.1.post5            pypi_0    pypi
pexpect                   4.9.0                    pypi_0    pypi
pillow                    10.4.0                   pypi_0    pypi
pip                       25.1               pyhc872135_2  
platformdirs              4.3.8                    pypi_0    pypi
plotly                    5.24.1                   pypi_0    pypi
prometheus-client         0.22.0                   pypi_0    pypi
prometheus-fastapi-instrumentator 7.1.0                    pypi_0    pypi
prompt-toolkit            3.0.51                   pypi_0    pypi
propcache                 0.3.1                    pypi_0    pypi
protobuf                  5.28.2                   pypi_0    pypi
psutil                    7.0.0                    pypi_0    pypi
ptyprocess                0.7.0                    pypi_0    pypi
pure-eval                 0.2.3                    pypi_0    pypi
py-cpuinfo                9.0.0                    pypi_0    pypi
pyairports                2.1.1                    pypi_0    pypi
pyarrow                   17.0.0                   pypi_0    pypi
pycountry                 24.6.1                   pypi_0    pypi
pycparser                 2.22                     pypi_0    pypi
pydantic                  2.9.2                    pypi_0    pypi
pydantic-core             2.23.4                   pypi_0    pypi
pygments                  2.19.1                   pypi_0    pypi
python                    3.10.16              he870216_1  
python-dateutil           2.9.0.post0              pypi_0    pypi
python-dotenv             1.0.1                    pypi_0    pypi
python-json-logger        3.3.0                    pypi_0    pypi
pytz                      2025.2                   pypi_0    pypi
pyyaml                    6.0.2                    pypi_0    pypi
pyzmq                     26.4.0                   pypi_0    pypi
ray                       2.37.0                   pypi_0    pypi
readline                  8.2                  h5eee18b_0  
referencing               0.36.2                   pypi_0    pypi
regex                     2024.11.6                pypi_0    pypi
requests                  2.32.3                   pypi_0    pypi
rfc3339-validator         0.1.4                    pypi_0    pypi
rfc3986-validator         0.1.1                    pypi_0    pypi
rpds-py                   0.25.1                   pypi_0    pypi
safetensors               0.4.5                    pypi_0    pypi
send2trash                1.8.3                    pypi_0    pypi
sentencepiece             0.2.0                    pypi_0    pypi
setuptools                78.1.1          py310h06a4308_0  
six                       1.17.0                   pypi_0    pypi
sniffio                   1.3.1                    pypi_0    pypi
soupsieve                 2.7                      pypi_0    pypi
sqlite                    3.45.3               h5eee18b_0  
stack-data                0.6.3                    pypi_0    pypi
starlette                 0.38.6                   pypi_0    pypi
sympy                     1.13.1                   pypi_0    pypi
tenacity                  9.1.2                    pypi_0    pypi
terminado                 0.18.1                   pypi_0    pypi
tiktoken                  0.7.0                    pypi_0    pypi
timm                      1.0.12                   pypi_0    pypi
tinycss2                  1.4.0                    pypi_0    pypi
tk                        8.6.14               h39e8969_0  
tokenizers                0.21.1                   pypi_0    pypi
tomli                     2.2.1                    pypi_0    pypi
torch                     2.5.0+cu121              pypi_0    pypi
torchvision               0.19.0                   pypi_0    pypi
tornado                   6.5.1                    pypi_0    pypi
tqdm                      4.66.5                   pypi_0    pypi
traitlets                 5.14.3                   pypi_0    pypi
transformers              4.52.4                   pypi_0    pypi
triton                    3.1.0                    pypi_0    pypi
types-python-dateutil     2.9.0.20250516           pypi_0    pypi
typing-extensions         4.13.2                   pypi_0    pypi
tzdata                    2025.2                   pypi_0    pypi
uri-template              1.3.0                    pypi_0    pypi
urllib3                   2.4.0                    pypi_0    pypi
uvicorn                   0.30.6                   pypi_0    pypi
uvloop                    0.21.0                   pypi_0    pypi
vllm                      0.6.2                    pypi_0    pypi
watchfiles                1.0.5                    pypi_0    pypi
wcwidth                   0.2.13                   pypi_0    pypi
webcolors                 24.11.1                  pypi_0    pypi
webencodings              0.5.1                    pypi_0    pypi
websocket-client          1.8.0                    pypi_0    pypi
websockets                15.0.1                   pypi_0    pypi
wheel                     0.45.1          py310h06a4308_0  
widgetsnbextension        4.0.14                   pypi_0    pypi
xformers                  0.0.27.post2             pypi_0    pypi
xxhash                    3.5.0                    pypi_0    pypi
xz                        5.6.4                h5eee18b_1  
yarl                      1.20.0                   pypi_0    pypi
zipp                      3.22.0                   pypi_0    pypi
zlib                      1.2.13               h5eee18b_1  
Package                  Version
------------------------ -----------
accelerate               1.7.0
anaconda-anon-usage      0.7.0
annotated-types          0.6.0
anthropic                0.52.1
anyio                    4.9.0
archspec                 0.2.3
boltons                  24.1.0
Brotli                   1.0.9
certifi                  2025.4.26
cffi                     1.17.1
charset-normalizer       3.3.2
conda                    25.3.1
conda-anaconda-telemetry 0.1.2
conda-anaconda-tos       0.1.3
conda-content-trust      0.2.0
conda-libmamba-solver    25.4.0
conda-package-handling   2.4.0
conda_package_streaming  0.11.0
cryptography             44.0.1
distro                   1.9.0
filelock                 3.18.0
frozendict               2.4.2
fsspec                   2025.5.1
h11                      0.16.0
hf-xet                   1.1.2
httpcore                 1.0.9
httpx                    0.28.1
huggingface-hub          0.32.3
idna                     3.7
Jinja2                   3.1.4
jiter                    0.10.0
jsonpatch                1.33
jsonpointer              2.1
libmambapy               2.0.5
markdown-it-py           2.2.0
MarkupSafe               3.0.2
mdurl                    0.1.0
menuinst                 2.2.0
mpmath                   1.3.0
networkx                 3.3
numpy                    2.2.6
nvidia-cublas-cu12       12.1.3.1
nvidia-cuda-cupti-cu12   12.1.105
nvidia-cuda-nvrtc-cu12   12.1.105
nvidia-cuda-runtime-cu12 12.1.105
nvidia-cudnn-cu12        9.1.0.70
nvidia-cufft-cu12        11.0.2.54
nvidia-curand-cu12       10.3.2.106
nvidia-cusolver-cu12     11.4.5.107
nvidia-cusparse-cu12     12.1.0.106
nvidia-nccl-cu12         2.21.5
nvidia-nvjitlink-cu12    12.1.105
nvidia-nvtx-cu12         12.1.105
openai                   1.82.1
packaging                24.2
pandas                   2.2.3
pip                      25.0
platformdirs             4.3.7
pluggy                   1.5.0
psutil                   7.0.0
pycosat                  0.6.6
pycparser                2.21
pydantic                 2.10.3
pydantic_core            2.27.1
Pygments                 2.19.1
PySocks                  1.7.1
python-dateutil          2.9.0.post0
pytz                     2025.2
PyYAML                   6.0.2
regex                    2024.11.6
requests                 2.32.3
rich                     13.9.4
ruamel.yaml              0.18.10
ruamel.yaml.clib         0.2.12
safetensors              0.5.3
setuptools               78.1.1
six                      1.17.0
sniffio                  1.3.1
sympy                    1.13.1
tokenizers               0.21.1
torch                    2.5.1+cu121
tqdm                     4.67.1
truststore               0.10.0
typing_extensions        4.12.2
tzdata                   2025.2
urllib3                  2.3.0
wheel                    0.45.1
zstandard                0.23.0

Currently Loaded Modules:
  1) stack/2024-05   3) cuda/12.2.1          5) eth_proxy   7) hdf5/1.14.3
  2) gcc/13.2.0      4) python/3.11.6_cuda   6) r/4.3.2     8) julia/1.10.3

 

Using Python at: /cluster/home/gcardenal/miniconda3/bin/python
Using torchrun at: /cluster/home/gcardenal/miniconda3/bin/torchrun
✅ openai imported successfully
{'SHELL': '/bin/bash', 'JUPYTER_CONFIG_DIR': '/cluster/home/gcardenal/.jupyterlab', 'JUPYTERHUB_ADMIN_ACCESS': '1', 'SLURM_JOB_USER': 'gcardenal', 'LIBGL_ALWAYS_INDIRECT': '1', 'SLURM_TASKS_PER_NODE': '1', 'SLURM_JOB_UID': '608619', 'no_proxy': 'api.wandb.ai,app.neptune.ai,jupyter.eu-dev.hpc.ethz.ch,jupyter-staging.euler.hpc.ethz.ch,jupyter.euler.hpc.ethz.ch,.consul,localhost,127.0.0.1,127.0.0.0/8,169.254.0.0/16', 'SLURM_TASK_PID': '3067870', 'CONDA_EXE': '/cluster/home/gcardenal/miniconda3/bin/conda', 'R_HOME': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/rlib/R', 'JUPYTERHUB_SERVICE_URL': 'https://0.0.0.0:0/user/gcardenal/', 'SLURM_JOB_GPUS': '6,7', 'PKG_CONFIG_PATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/lib/pkgconfig:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/rlib/pkgconfig:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/lib/pkgconfig', 'SLURM_LOCALID': '0', 'PYTHONNOUSERSITE': '1', 'SLURM_SUBMIT_DIR': '/cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation', 'HOSTNAME': 'eu-ts-02', 'SLURMD_NODENAME': 'eu-ts-02', 'JUPYTERHUB_API_TOKEN': 'af64847746424f48b19949dac9d1a3c1', 'SLURM_JOB_START_TIME': '1748698991', 'HYDRA_LAUNCHER_EXTRA_ARGS': '--external-launcher', '_ModuleTable007_': 'fQo=', '_ModuleTable002_': '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', 'HDF5_EULER_ROOT': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr', 'CPUS': '8', '__LMOD_REF_COUNT_MODULEPATH': '/cluster/software/lmods:1', '__LMOD_REF_COUNT_CPLUS_INCLUDE_PATH': '/cluster/software/manual/julia/1.10.3/x86_64/include:1', 'JUPYTERHUB_BASE_URL': '/', '_ModuleTable005_': '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', 'SLURM_CLUSTER_NAME': 'euler-24-production', 'SLURM_JOB_END_TIME': '1748785391', 'SLURM_CPUS_ON_NODE': '8', 'SLURM_JOB_CPUS_PER_NODE': '8', 'LMOD_DIR': '/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/lmod-8.7.24-ou4i7x2rgiaysly4vgawaga6muhkdye4/lmod/lmod/libexec', 'SLURM_GPUS_ON_NODE': '2', 'PWD': '/cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation', 'PRTE_MCA_plm_slurm_args': '--external-launcher', 'SLURM_GTIDS': '0', 'LOGNAME': 'gcardenal', 'CONDA_PREFIX': '/cluster/home/gcardenal/miniconda3/envs/vllm_2', 'SLURM_JOB_PARTITION': 'gpupr.24h', 'SCRIPTS_PATH': '/cluster/software/others/services/jupyterhub/scripts', 'MODULESHOME': '/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/lmod-8.7.24-ou4i7x2rgiaysly4vgawaga6muhkdye4/lmod/lmod', 'JUPYTER_SERVER_URL': 'https://eu-g5-008-3:33099/user/gcardenal/', 'MANPATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/share/man:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/share/man:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/share/man::', 'SLURM_TRES_PER_TASK': 'cpu=8', 'PYTHON_EULER_ROOT': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i', 'SLURM_JOB_NUM_NODES': '1', 'CXX': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/bin/g++', '__LMOD_REF_COUNT_CMAKE_PREFIX_PATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog:1', '__LMOD_REF_COUNT_INCLUDE': '/cluster/software/manual/julia/1.10.3/x86_64/include:1', 'SLURM_JOBID': '33561479', 'SLURM_GPUS': 'nvidia_a100_80gb_pcie:2', 'ftp_proxy': 'http://proxy.service.consul:3128', 'JUPYTERHUB_SERVER_NAME': '', 'SLURM_JOB_QOS': 'es_ilic/gpupr/24', 'I_MPI_HYDRA_BOOTSTRAP_EXEC_EXTRA_ARGS': '--external-launcher', 'JUPYTER_DIR': '/', 'LINES': '54', 'GI_TYPELIB_PATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/pango-1.50.13-m6jqr7uchlpizk7kjhwpq6yl56vdtjb2/lib/girepository-1.0:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/harfbuzz-7.3.0-kfcjmvrteszehgnzwgjp5mmiyyhiggsc/lib/girepository-1.0', '__LMOD_REF_COUNT_PATH': '/cluster/software/manual/julia/1.10.3/x86_64/bin:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/bin:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/bin:1;/cluster/software/stacks/2024-05/python-cuda/3.11.6/bin:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt/bin:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/bin:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/bin:1;/usr/local/bin:2;/usr/local/sbin:1;/usr/sbin:1;/usr/bin:1;/sbin:1;/bin:1;/cluster/slurm/apps/bin:1', 'HOME': '/cluster/home/gcardenal', '_ModuleTable_Sz_': '7', '__LMOD_REF_COUNT_LIBRARY_PATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/lib:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt/lib64:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/lib:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/lib64:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/lib:1', 'LANG': 'C.UTF-8', '__LMOD_REF_COUNT_PKG_CONFIG_PATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/lib/pkgconfig:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/rlib/pkgconfig:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/lib/pkgconfig:1', 'SLURM_PROCID': '0', 'JPY_API_TOKEN': 'af64847746424f48b19949dac9d1a3c1', 'COLUMNS': '113', '__LMOD_REF_COUNT_XLOCALEDIR': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/libx11-1.8.4-pdy3nkfzllbwmmmhnxrwhxonuqg4v2b7/share/X11/locale:1', 'SCRATCH': '/cluster/scratch/gcardenal', '__LMOD_REF_COUNT_CPATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/include:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/include:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt/include:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/include:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/include:1', 'LMOD_SETTARG_FULL_SUPPORT': 'no', 'JUPYTERLAB_ROOT': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i', 'CONDA_PROMPT_MODIFIER': '(vllm_2) ', 'TMPDIR': '/scratch/tmp.33561479.gcardenal', 'JUPYTERHUB_SERVICE_PREFIX': '/user/gcardenal/', 'CUDA_EULER_ROOT': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt', 'CMAKE_PREFIX_PATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog', 'JUPYTERHUB_OAUTH_CALLBACK_URL': '/user/gcardenal/oauth_callback', 'https_proxy': 'http://proxy.service.consul:3128', 'R_EULER_ROOT': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn', 'SLURM_CPUS_PER_TASK': '8', 'SLURM_NTASKS': '1', 'CONFIG_PATH': '/cluster/home/gcardenal/.config/euler/jupyterhub', 'SLURM_TOPOLOGY_ADDR': '.euler_a100_80_lca_ib.eu-ts-02', 'LMOD_VERSION': '8.7.24', 'JUPYTER_CONFIG_PATH': '/cluster/home/gcardenal/.jupyterlab:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/share/jupyter', 'LMOD_PACKAGE_PATH': '/cluster/software/etc/lmod', 'JUPYTERHUB_OAUTH_CLIENT_ALLOWED_SCOPES': '[]', '_ModuleTable003_': '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', 'HYDRA_BOOTSTRAP': 'slurm', '__LMOD_REF_COUNT_XDG_DATA_DIRS': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/pango-1.50.13-m6jqr7uchlpizk7kjhwpq6yl56vdtjb2/share:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/harfbuzz-7.3.0-kfcjmvrteszehgnzwgjp5mmiyyhiggsc/share:1', 'PROXY_PORT': '33099', 'SLURM_TOPOLOGY_ADDR_PATTERN': 'switch.switch.node', 'CUDA_VISIBLE_DEVICES': '0,1', 'SLURM_MEM_PER_CPU': '20480', 'LMOD_PKG': '/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/lmod-8.7.24-ou4i7x2rgiaysly4vgawaga6muhkdye4/lmod/lmod', 'SLURM_SCRIPT_CONTEXT': 'prolog_task', 'JUPYTER_SERVER_ROOT': '/', 'PYTHONPATH': '/cluster/home/gcardenal/miniconda3/bin:/cluster/home/gcardenal/miniconda3/bin:/cluster/home/gcardenal/miniconda3/bin:/cluster/scratch/gcardenal/miniconda3/bin:/cluster/home/gcardenal/miniconda3/bin:/cluster/home/gcardenal/miniconda3/bin:/cluster/home/gcardenal/miniconda3/bin:/cluster/scratch/gcardenal/miniconda3/bin:/cluster/software/manual/julia/1.10.3/x86_64/bin:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/bin:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/bin:/cluster/software/stacks/2024-05/python-cuda/3.11.6/bin:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt/bin:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/bin:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/bin:/usr/local/bin:/usr/local/sbin:/usr/sbin:/usr/bin:/sbin:/bin:/cluster/slurm/apps/bin:/cluster/software/bin:/cluster/home/gcardenal/.local/bin:/cluster/home/gcardenal/bin', 'TERM': 'xterm-256color', 'JUPYTERHUB_SSL_KEYFILE': '.config/euler/jupyterhub/jupyter.key', 'JUPYTER_EXTRA_ARGS': '', 'ZES_ENABLE_SYSMAN': '1', 'CPLUS_INCLUDE_PATH': '/cluster/software/manual/julia/1.10.3/x86_64/include', 'XLOCALEDIR': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/libx11-1.8.4-pdy3nkfzllbwmmmhnxrwhxonuqg4v2b7/share/X11/locale', 'F77': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/bin/gfortran', '__LMOD_REF_COUNT_GI_TYPELIB_PATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/pango-1.50.13-m6jqr7uchlpizk7kjhwpq6yl56vdtjb2/lib/girepository-1.0:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/harfbuzz-7.3.0-kfcjmvrteszehgnzwgjp5mmiyyhiggsc/lib/girepository-1.0:1', 'USER': 'gcardenal', 'LIBRARY_PATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/lib:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt/lib64:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/lib:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/lib64:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/lib', 'SLURM_NODELIST': 'eu-ts-02', 'ENVIRONMENT': 'BATCH', 'CONDA_SHLVL': '2', 'LOADEDMODULES': 'stack/2024-05:gcc/13.2.0:cuda/12.2.1:python/3.11.6_cuda:eth_proxy:r/4.3.2:hdf5/1.14.3:julia/1.10.3', 'SLURM_JOB_ACCOUNT': 'gpupr/es_ilic', 'SLURM_PRIO_PROCESS': '0', 'JUPYTERHUB_OAUTH_ACCESS_SCOPES': '["access:servers!server=gcardenal/", "access:servers!user=gcardenal"]', 'SLURM_NPROCS': '1', 'INCLUDE': '/cluster/software/manual/julia/1.10.3/x86_64/include', 'JUPYTERHUB_COOKIE_HOST_PREFIX_ENABLED': '0', 'LMOD_ROOT': '/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/lmod-8.7.24-ou4i7x2rgiaysly4vgawaga6muhkdye4/lmod', 'NVHPC_CUDA_HOME': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt', 'SHLVL': '4', 'SLURM_NNODES': '1', 'PYXTERM_DIMENSIONS': '80x25', 'BASH_ENV': '/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/lmod-8.7.24-ou4i7x2rgiaysly4vgawaga6muhkdye4/lmod/lmod/init/bash', '_ModuleTable006_': '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', 'I_MPI_PMI_LIBRARY': '/cluster/apps/slurm/lib/libpmi2.so', 'JULIA_ROOT': '/cluster/software/manual/julia/1.10.3/x86_64', 'JUPYTERHUB_API_URL': 'https://jupyter.euler.hpc.ethz.ch/hub/api', 'JUPYTER_PATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/share/jupyter', 'JUPYTERLAB_DIR': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/share/jupyter/lab', 'JUPYTERHUB_CLIENT_ID': 'jupyterhub-user-gcardenal', 'JUPYTERHUB_OAUTH_SCOPES': '["access:servers!server=gcardenal/", "access:servers!user=gcardenal"]', '__LMOD_REF_COUNT_MANPATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/share/man:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/share/man:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/share/man:1;:3', 'JUPYTER_HOME': '/cluster/home/gcardenal', 'http_proxy': 'http://proxy.service.consul:3128', 'SLURM_SUBMIT_HOST': 'eu-g5-008-3', 'JUPYTERHUB_HOST': '', '_ModuleTable001_': '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', 'CONDA_PYTHON_EXE': '/cluster/home/gcardenal/miniconda3/bin/python', 'LD_LIBRARY_PATH': '/cluster/software/manual/julia/1.10.3/x86_64/lib:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/rlib:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/rlib/R/lib:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt/lib64:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/lib:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/lib64:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/lib:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/lib', 'LMOD_FAMILY_COMPILER': 'gcc', 'SLURM_JOB_ID': '33561479', 'SLURM_NODEID': '0', '_ModuleTable004_': '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', 'CONDA_DEFAULT_ENV': 'vllm_2', 'OMP_NUM_THREADS': '8', 'FC': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/bin/gfortran', 'TMOUT': '86400', 'LMOD_FAMILY_COMPILER_VERSION': '13.2.0', 'CUDA_HOME': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt', '__LMOD_REF_COUNT_C_INCLUDE_PATH': '/cluster/software/manual/julia/1.10.3/x86_64/include:1', 'XDG_DATA_DIRS': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/pango-1.50.13-m6jqr7uchlpizk7kjhwpq6yl56vdtjb2/share:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/harfbuzz-7.3.0-kfcjmvrteszehgnzwgjp5mmiyyhiggsc/share', 'SERVICE_PORT': '47189', 'JUPYTERHUB_SSL_CLIENT_CA': '.config/euler/jupyterhub/jupyter.ca', 'SLURM_CONF': '/cluster/slurm/adm/etc/slurm.conf', 'PATH': '/cluster/home/gcardenal/miniconda3/bin:/cluster/home/gcardenal/miniconda3/bin:/cluster/home/gcardenal/miniconda3/envs/vllm_2/bin:/cluster/home/gcardenal/miniconda3/bin:/cluster/home/gcardenal/miniconda3/bin:/cluster/home/gcardenal/miniconda3/bin:/cluster/scratch/gcardenal/miniconda3/bin:/cluster/software/manual/julia/1.10.3/x86_64/bin:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/bin:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/bin:/cluster/software/stacks/2024-05/python-cuda/3.11.6/bin:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt/bin:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/bin:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/bin:/usr/local/bin:/usr/local/sbin:/usr/sbin:/usr/bin:/sbin:/bin:/cluster/slurm/apps/bin:/cluster/software/bin:/cluster/home/gcardenal/.local/bin:/cluster/home/gcardenal/bin', 'SLURM_JOB_NAME': 'final_results', 'MODULEPATH': '/cluster/software/lmods', 'CC': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/bin/gcc', '_LMFILES_': '/cluster/software/lmods/stack/2024-05.lua:/cluster/software/stacks/2024-05/spack/share/spack/lmod/linux-ubuntu22.04-x86_64/Core/gcc/13.2.0.lua:/cluster/software/stacks/2024-05/spack/share/spack/lmod/linux-ubuntu22.04-x86_64/gcc/13.2.0/cuda/12.2.1.lua:/cluster/software/stacks/2024-05/spack/share/spack/lmod/linux-ubuntu22.04-x86_64/gcc/13.2.0/python/3.11.6_cuda.lua:/cluster/software/lmods/eth_proxy.lua:/cluster/software/stacks/2024-05/spack/share/spack/lmod/linux-ubuntu22.04-x86_64/gcc/13.2.0/r/4.3.2.lua:/cluster/software/stacks/2024-05/spack/share/spack/lmod/linux-ubuntu22.04-x86_64/gcc/13.2.0/hdf5/1.14.3.lua:/cluster/software/lmods/julia/1.10.3.lua', 'LMOD_CMD': '/cluster/software/stacks/2024-06/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-12.2.0/lmod-8.7.24-ou4i7x2rgiaysly4vgawaga6muhkdye4/lmod/lmod/libexec/lmod', 'C_INCLUDE_PATH': '/cluster/software/manual/julia/1.10.3/x86_64/include', 'JUPYTERHUB_USER': 'gcardenal', 'MAIL': '/var/mail/gcardenal', 'JUPYTERHUB_SSL_CERTFILE': '.config/euler/jupyterhub/jupyter.crt', '__LMOD_REF_COUNT_LD_LIBRARY_PATH': '/cluster/software/manual/julia/1.10.3/x86_64/lib:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/rlib:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/rlib/R/lib:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt/lib64:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/lib:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/lib64:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/lib:1;/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/lib:2', 'JUPYTERHUB_ACTIVITY_URL': 'https://jupyter.euler.hpc.ethz.ch/hub/api/users/gcardenal/activity', 'CONDA_PREFIX_1': '/cluster/scratch/gcardenal/miniconda3', 'OMPI_MCA_plm_slurm_args': '--external-launcher', 'SLURM_JOB_GID': '492010', 'CPATH': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/hdf5-1.14.3-djiamwqmf55x25kua4cbbio5newzctbr/include:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/r-4.3.2-c6hxdn6t4ao6fbqv4cg2xqinhwtwdwbn/include:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/cuda-12.2.1-fv6yilrnidoe35nh24iszjkf63bihikt/include:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-13.2.0/python-3.11.6-m4n2ny4dwaqmeobuqquo3gpyw2bct67i/include:/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog/include', 'GCC_EULER_ROOT': '/cluster/software/stacks/2024-05/spack/opt/spack/linux-ubuntu22.04-x86_64_v3/gcc-11.4.0/gcc-13.2.0-6t2bdhlkrktlyopht3nbmjz3emlsqeog', 'OLDPWD': '/cluster/home/gcardenal', 'SLURM_JOB_NODELIST': 'eu-ts-02', 'CONSUL_HTTP_ADDR': 'unix:///var/run/consul/http.sock', 'I_MPI_HYDRA_BOOTSTRAP': 'slurm', 'BASH_FUNC_ml%%': '() {  eval "$($LMOD_DIR/ml_cmd "$@")"\n}', 'BASH_FUNC_module%%': '() {  if [ -z "${LMOD_SH_DBG_ON+x}" ]; then\n case "$-" in \n *v*x*)\n __lmod_sh_dbg=\'vx\'\n ;;\n *v*)\n __lmod_sh_dbg=\'v\'\n ;;\n *x*)\n __lmod_sh_dbg=\'x\'\n ;;\n esac;\n fi;\n if [ -n "${__lmod_sh_dbg:-}" ]; then\n set +$__lmod_sh_dbg;\n echo "Shell debugging temporarily silenced: export LMOD_SH_DBG_ON=1 for Lmod\'s output" 1>&2;\n fi;\n eval "$($LMOD_CMD shell "$@")" && eval "$(${LMOD_SETTARG_CMD:-:} -s sh)";\n __lmod_my_status=$?;\n if [ -n "${__lmod_sh_dbg:-}" ]; then\n echo "Shell debugging restarted" 1>&2;\n set -$__lmod_sh_dbg;\n fi;\n unset __lmod_sh_dbg;\n return $__lmod_my_status\n}', '_': '/cluster/home/gcardenal/miniconda3/bin/python'}
Traceback (most recent call last):
  File "<string>", line 1, in <module>
    from transformers import Gemma3ForCausalLM; print('✅importing Gemma3 It works')
    ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
ModuleNotFoundError: No module named 'transformers'
Testing Slurm Variables...
SLURM_JOB_USER=gcardenal
SLURM_TASKS_PER_NODE=1
SLURM_JOB_UID=608619
SLURM_TASK_PID=3067870
SLURM_JOB_GPUS=6,7
SLURM_LOCALID=0
SLURM_SUBMIT_DIR=/cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation
SLURMD_NODENAME=eu-ts-02
SLURM_JOB_START_TIME=1748698991
SLURM_CLUSTER_NAME=euler-24-production
SLURM_JOB_END_TIME=1748785391
SLURM_CPUS_ON_NODE=8
SLURM_JOB_CPUS_PER_NODE=8
SLURM_GPUS_ON_NODE=2
SLURM_GTIDS=0
SLURM_JOB_PARTITION=gpupr.24h
SLURM_TRES_PER_TASK=cpu=8
SLURM_JOB_NUM_NODES=1
SLURM_JOBID=33561479
SLURM_GPUS=nvidia_a100_80gb_pcie:2
SLURM_JOB_QOS=es_ilic/gpupr/24
SLURM_PROCID=0
SLURM_CPUS_PER_TASK=8
SLURM_NTASKS=1
SLURM_TOPOLOGY_ADDR=.euler_a100_80_lca_ib.eu-ts-02
SLURM_TOPOLOGY_ADDR_PATTERN=switch.switch.node
SLURM_MEM_PER_CPU=20480
SLURM_SCRIPT_CONTEXT=prolog_task
SLURM_NODELIST=eu-ts-02
SLURM_JOB_ACCOUNT=gpupr/es_ilic
SLURM_PRIO_PROCESS=0
SLURM_NPROCS=1
SLURM_NNODES=1
SLURM_SUBMIT_HOST=eu-g5-008-3
SLURM_JOB_ID=33561479
SLURM_NODEID=0
SLURM_CONF=/cluster/slurm/adm/etc/slurm.conf
SLURM_JOB_NAME=final_results
SLURM_JOB_GID=492010
SLURM_JOB_NODELIST=eu-ts-02
Sat May 31 15:43:24 2025       
+-----------------------------------------------------------------------------------------+
| NVIDIA-SMI 570.133.20             Driver Version: 570.133.20     CUDA Version: 12.8     |
|-----------------------------------------+------------------------+----------------------+
| GPU  Name                 Persistence-M | Bus-Id          Disp.A | Volatile Uncorr. ECC |
| Fan  Temp   Perf          Pwr:Usage/Cap |           Memory-Usage | GPU-Util  Compute M. |
|                                         |                        |               MIG M. |
|=========================================+========================+======================|
|   0  NVIDIA A100 80GB PCIe          On  |   00000000:E3:00.0 Off |                    0 |
| N/A   44C    P0             49W /  300W |       0MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
|   1  NVIDIA A100 80GB PCIe          On  |   00000000:E4:00.0 Off |                    0 |
| N/A   33C    P0             47W /  300W |       0MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
                                                                                         
+-----------------------------------------------------------------------------------------+
| Processes:                                                                              |
|  GPU   GI   CI              PID   Type   Process name                        GPU Memory |
|        ID   ID                                                               Usage      |
|=========================================================================================|
|  No running processes found                                                             |
+-----------------------------------------------------------------------------------------+
Node IP: 10.205.9.18
JobId=33561479 JobName=final_results
   UserId=gcardenal(608619) GroupId=gcardenal-group(492010) MCS_label=N/A
   Priority=5773 Nice=0 Account=gpupr/es_ilic QOS=es_ilic/gpupr/24
   JobState=RUNNING Reason=None Dependency=(null)
   Requeue=0 Restarts=0 BatchFlag=1 Reboot=0 ExitCode=0:0
   RunTime=00:00:13 TimeLimit=1-00:00:00 TimeMin=N/A
   SubmitTime=2025-05-31T15:42:12 EligibleTime=2025-05-31T15:42:12
   AccrueTime=2025-05-31T15:42:12
   StartTime=2025-05-31T15:43:11 EndTime=2025-06-01T15:43:11 Deadline=N/A
   SuspendTime=None SecsPreSuspend=0 LastSchedEval=2025-05-31T15:43:11 Scheduler=Backfill
   Partition=gpupr.24h AllocNode:Sid=eu-g5-008-3:1820250
   ReqNodeList=(null) ExcNodeList=(null)
   NodeList=eu-ts-02
   BatchHost=eu-ts-02
   NumNodes=1 NumCPUs=8 NumTasks=1 CPUs/Task=8 ReqB:S:C:T=0:0:*:*
   ReqTRES=cpu=8,mem=160G,node=1,billing=694681,gres/gpu=2,gres/gpu:nvidia_a100_80gb_pcie=2,gres/gpumem=85899345920
   AllocTRES=cpu=8,mem=160G,node=1,billing=694681,gres/gpu=2,gres/gpu:nvidia_a100_80gb_pcie=2,gres/gpumem=0
   Socks/Node=* NtasksPerN:B:S:C=0:0:*:1 CoreSpec=*
   MinCPUsNode=8 MinMemoryCPU=20G MinTmpDiskNode=0
   Features=(null) DelayBoot=00:00:00
   OverSubscribe=OK Contiguous=0 Licenses=(null) Network=(null)
   Command=/cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation/generate_answers-medgemma.sh
   WorkDir=/cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation
   StdErr=/cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation/final_results33561479.out
   StdIn=/dev/null
   StdOut=/cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation/final_results33561479.out
   TresPerJob=gres/gpu:nvidia_a100_80gb_pcie:2
   TresPerNode=gres/gpumem:80G
   TresPerTask=cpu=8
   

Conda env: /cluster/home/gcardenal/miniconda3/envs/vllm_2
/cluster/home/gcardenal/miniconda3/bin/python
Traceback (most recent call last):
  File "<string>", line 1, in <module>
    import transformers; print(transformers.__version__)
    ^^^^^^^^^^^^^^^^^^^
ModuleNotFoundError: No module named 'transformers'
Collecting transformers==4.52.4
  Using cached transformers-4.52.4-py3-none-any.whl.metadata (38 kB)
Requirement already satisfied: filelock in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from transformers==4.52.4) (3.18.0)
Requirement already satisfied: huggingface-hub<1.0,>=0.30.0 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from transformers==4.52.4) (0.32.3)
Requirement already satisfied: numpy>=1.17 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from transformers==4.52.4) (2.2.6)
Requirement already satisfied: packaging>=20.0 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from transformers==4.52.4) (24.2)
Requirement already satisfied: pyyaml>=5.1 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from transformers==4.52.4) (6.0.2)
Requirement already satisfied: regex!=2019.12.17 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from transformers==4.52.4) (2024.11.6)
Requirement already satisfied: requests in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from transformers==4.52.4) (2.32.3)
Requirement already satisfied: tokenizers<0.22,>=0.21 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from transformers==4.52.4) (0.21.1)
Requirement already satisfied: safetensors>=0.4.3 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from transformers==4.52.4) (0.5.3)
Requirement already satisfied: tqdm>=4.27 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from transformers==4.52.4) (4.67.1)
Requirement already satisfied: fsspec>=2023.5.0 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from huggingface-hub<1.0,>=0.30.0->transformers==4.52.4) (2025.5.1)
Requirement already satisfied: typing-extensions>=3.7.4.3 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from huggingface-hub<1.0,>=0.30.0->transformers==4.52.4) (4.12.2)
Requirement already satisfied: hf-xet<2.0.0,>=1.1.2 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from huggingface-hub<1.0,>=0.30.0->transformers==4.52.4) (1.1.2)
Requirement already satisfied: charset-normalizer<4,>=2 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from requests->transformers==4.52.4) (3.3.2)
Requirement already satisfied: idna<4,>=2.5 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from requests->transformers==4.52.4) (3.7)
Requirement already satisfied: urllib3<3,>=1.21.1 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from requests->transformers==4.52.4) (2.3.0)
Requirement already satisfied: certifi>=2017.4.17 in /cluster/home/gcardenal/miniconda3/lib/python3.13/site-packages (from requests->transformers==4.52.4) (2025.4.26)
Using cached transformers-4.52.4-py3-none-any.whl (10.5 MB)
Installing collected packages: transformers
Successfully installed transformers-4.52.4
Running in standalone mode...
Transformers version inside run: 4.52.4
Running run_inference.sh...
Found existing installation: transformers 4.52.4
Uninstalling transformers-4.52.4:
  Successfully uninstalled transformers-4.52.4
Error while loading conda entry point: anaconda-anon-usage-plugin (No module named 'anaconda_anon_usage')
Found existing installation: torch 2.5.0+cu121
Uninstalling torch-2.5.0+cu121:
  Successfully uninstalled torch-2.5.0+cu121
Looking in indexes: https://download.pytorch.org/whl/cu121
Collecting torch==2.5.0
  Using cached https://download.pytorch.org/whl/cu121/torch-2.5.0%2Bcu121-cp310-cp310-linux_x86_64.whl (780.4 MB)
Requirement already satisfied: filelock in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (3.16.1)
Requirement already satisfied: typing-extensions>=4.8.0 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (4.13.2)
Requirement already satisfied: networkx in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (3.3)
Requirement already satisfied: jinja2 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (3.1.4)
Requirement already satisfied: fsspec in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (2024.6.1)
Requirement already satisfied: nvidia-cuda-nvrtc-cu12==12.1.105 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (12.1.105)
Requirement already satisfied: nvidia-cuda-runtime-cu12==12.1.105 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (12.1.105)
Requirement already satisfied: nvidia-cuda-cupti-cu12==12.1.105 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (12.1.105)
Requirement already satisfied: nvidia-cudnn-cu12==9.1.0.70 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (9.1.0.70)
Requirement already satisfied: nvidia-cublas-cu12==12.1.3.1 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (12.1.3.1)
Requirement already satisfied: nvidia-cufft-cu12==11.0.2.54 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (11.0.2.54)
Requirement already satisfied: nvidia-curand-cu12==10.3.2.106 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (10.3.2.106)
Requirement already satisfied: nvidia-cusolver-cu12==11.4.5.107 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (11.4.5.107)
Requirement already satisfied: nvidia-cusparse-cu12==12.1.0.106 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (12.1.0.106)
Requirement already satisfied: nvidia-nccl-cu12==2.21.5 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (2.21.5)
Requirement already satisfied: nvidia-nvtx-cu12==12.1.105 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (12.1.105)
Requirement already satisfied: triton==3.1.0 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (3.1.0)
Requirement already satisfied: sympy==1.13.1 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from torch==2.5.0) (1.13.1)
Requirement already satisfied: nvidia-nvjitlink-cu12 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from nvidia-cusolver-cu12==11.4.5.107->torch==2.5.0) (12.9.41)
Requirement already satisfied: mpmath<1.4,>=1.1.0 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from sympy==1.13.1->torch==2.5.0) (1.3.0)
Requirement already satisfied: MarkupSafe>=2.0 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from jinja2->torch==2.5.0) (3.0.2)
Installing collected packages: torch
ERROR: pip's dependency resolver does not currently take into account all the packages that are installed. This behaviour is the source of the following dependency conflicts.
vllm 0.6.2 requires transformers>=4.45.0, which is not installed.
torchvision 0.19.0 requires torch==2.4.0, but you have torch 2.5.0+cu121 which is incompatible.
vllm 0.6.2 requires torch==2.4.0, but you have torch 2.5.0+cu121 which is incompatible.
xformers 0.0.27.post2 requires torch==2.4.0, but you have torch 2.5.0+cu121 which is incompatible.
Successfully installed torch-2.5.0+cu121
Collecting transformers
  Using cached transformers-4.52.4-py3-none-any.whl.metadata (38 kB)
Requirement already satisfied: filelock in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from transformers) (3.16.1)
Requirement already satisfied: huggingface-hub<1.0,>=0.30.0 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from transformers) (0.32.3)
Requirement already satisfied: numpy>=1.17 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from transformers) (1.26.4)
Requirement already satisfied: packaging>=20.0 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from transformers) (25.0)
Requirement already satisfied: pyyaml>=5.1 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from transformers) (6.0.2)
Requirement already satisfied: regex!=2019.12.17 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from transformers) (2024.11.6)
Requirement already satisfied: requests in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from transformers) (2.32.3)
Requirement already satisfied: tokenizers<0.22,>=0.21 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from transformers) (0.21.1)
Requirement already satisfied: safetensors>=0.4.3 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from transformers) (0.4.5)
Requirement already satisfied: tqdm>=4.27 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from transformers) (4.66.5)
Requirement already satisfied: fsspec>=2023.5.0 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from huggingface-hub<1.0,>=0.30.0->transformers) (2024.6.1)
Requirement already satisfied: typing-extensions>=3.7.4.3 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from huggingface-hub<1.0,>=0.30.0->transformers) (4.13.2)
Requirement already satisfied: hf-xet<2.0.0,>=1.1.2 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from huggingface-hub<1.0,>=0.30.0->transformers) (1.1.2)
Requirement already satisfied: charset-normalizer<4,>=2 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from requests->transformers) (3.3.2)
Requirement already satisfied: idna<4,>=2.5 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from requests->transformers) (3.10)
Requirement already satisfied: urllib3<3,>=1.21.1 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from requests->transformers) (2.4.0)
Requirement already satisfied: certifi>=2017.4.17 in /cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages (from requests->transformers) (2024.8.30)
Using cached transformers-4.52.4-py3-none-any.whl (10.5 MB)
Installing collected packages: transformers
ERROR: pip's dependency resolver does not currently take into account all the packages that are installed. This behaviour is the source of the following dependency conflicts.
vllm 0.6.2 requires torch==2.4.0, but you have torch 2.5.0+cu121 which is incompatible.
Successfully installed transformers-4.52.4
Inside srun:
/cluster/home/gcardenal/miniconda3/envs/vllm_2/bin/python
✅ Python version: 3.10.16 (main, Dec 11 2024, 16:24:50) [GCC 11.2.0]
✅ Transformers version: 4.52.4
2.5.0+cu121
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/run.py:897] 
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/run.py:897] **************************************
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/run.py:897] Rendezvous info:
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/run.py:897] --rdzv-backend=c10d --rdzv-endpoint=localhost:0 --rdzv-id=8ac0266c-1e83-48bc-af5d-f164bd2615f2
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/run.py:897] **************************************
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/run.py:897] 
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194] Starting elastic_operator with launch configs:
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   entrypoint       : get_model_answers_and_prompt_generation.py
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   min_nodes        : 1
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   max_nodes        : 1
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   nproc_per_node   : 1
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   run_id           : 8ac0266c-1e83-48bc-af5d-f164bd2615f2
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   rdzv_backend     : c10d
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   rdzv_endpoint    : localhost:0
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   rdzv_configs     : {'timeout': 900}
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   max_restarts     : 0
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   monitor_interval : 0.1
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   log_dir          : /scratch/tmp.33561479.gcardenal/torchelastic_qsnqj463
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194]   metrics_cfg      : {}
I0531 15:44:58.073000 3068057 site-packages/torch/distributed/launcher/api.py:194] 
I0531 15:44:58.087000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:845] [default] starting workers for entrypoint: python3.10
I0531 15:44:58.088000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:662] [default] Rendezvous'ing worker group
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525] [default] Rendezvous complete for workers. Result:
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525]   restart_count=0
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525]   master_addr=localhost
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525]   master_port=45959
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525]   group_rank=0
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525]   group_world_size=1
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525]   local_ranks=[0]
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525]   role_ranks=[0]
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525]   global_ranks=[0]
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525]   role_world_sizes=[1]
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525]   global_world_sizes=[1]
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:525] 
I0531 15:44:58.406000 3068057 site-packages/torch/distributed/elastic/agent/server/api.py:670] [default] Starting worker group
I0531 15:44:58.407000 3068057 site-packages/torch/distributed/elastic/agent/server/local_elastic_agent.py:291] use_agent_store: True
I0531 15:44:58.407000 3068057 site-packages/torch/distributed/elastic/agent/server/local_elastic_agent.py:192] Environment variable 'TORCHELASTIC_ENABLE_FILE_TIMER' not found. Do not start FileTimerServer.
I0531 15:44:58.407000 3068057 site-packages/torch/distributed/elastic/agent/server/local_elastic_agent.py:229] Environment variable 'TORCHELASTIC_HEALTH_CHECK_PORT' not found. Do not start health check.
✅ transformers version being used: 4.52.4
✅ Python executable: /cluster/home/gcardenal/miniconda3/envs/vllm_2/bin/python3.10
✅ sys.path: ['/cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation', '/cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python310.zip', '/cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10', '/cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/lib-dynload', '/cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages']
Loading MedGemma-3-27B model locally...
Loading checkpoint shards:   0%|                                                         | 0/11 [00:00<?, ?it/s]Loading checkpoint shards:  27%|█████████████▎                                   | 3/11 [00:00<00:00, 19.40it/s]Loading checkpoint shards:  45%|██████████████████████▎                          | 5/11 [00:00<00:00, 17.52it/s]Loading checkpoint shards:  64%|███████████████████████████████▏                 | 7/11 [00:00<00:00, 16.91it/s]Loading checkpoint shards:  82%|████████████████████████████████████████         | 9/11 [00:00<00:00, 15.89it/s]Loading checkpoint shards: 100%|████████████████████████████████████████████████| 11/11 [00:00<00:00, 16.55it/s]Loading checkpoint shards: 100%|████████████████████████████████████████████████| 11/11 [00:00<00:00, 16.79it/s]
Starting inference for question (MedGemma-3-27B): How is HIV diagnosed?
Device set to use cuda:0
/cluster/home/gcardenal/miniconda3/envs/vllm_2/lib/python3.10/site-packages/torch/_inductor/compile_fx.py:167: UserWarning: TensorFloat32 tensor cores for float32 matrix multiplication available but not enabled. Consider setting `torch.set_float32_matmul_precision('high')` for better performance.
  warnings.warn(
Answer for question (MedGemma-3-27B): HIV is diagnosed using a combination of methods, primarily blood tests.

1.  **Antibody Tests:** These look for antibodies your immune system makes in response to HIV. They can be done via blood draw or oral fluid. Rapid antibody tests provide results in about 30 minutes, while lab-based tests take a few days.
2.  **Antigen/Antibody Tests (4th Generation):** These look for both HIV antibodies and the p24 antigen (part of the virus itself). The p24 antigen appears earlier than antibodies, allowing for earlier detection. These are usually blood tests.
3.  **Nucleic Acid Tests (NAT):** These look directly for the virus's genetic material (RNA) in the blood. NATs are the most expensive and are typically used when someone has had a recent high-risk exposure or has symptoms of acute HIV infection.

A positive result on an initial test is always confirmed with a second, different type of test.
Starting inference for question (MedGemma-3-27B): What are the different stages of HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV infection typically progresses through three stages:

1.  **Acute HIV Infection:** This is the earliest stage, occurring within 2 to 4 weeks after infection. Many people experience flu-like symptoms. The virus is highly active and easily transmissible during this stage.
2.  **Chronic HIV Infection (Clinical Latency):** The virus continues to replicate but at lower levels. People may not have symptoms for many years, but the virus is still active and can be transmitted. With treatment, people can stay in this stage for decades.
3.  **Acquired Immunodeficiency Syndrome (AIDS):** This is the most severe stage. The immune system is severely damaged, leaving the body vulnerable to opportunistic infections and cancers. This stage occurs when the CD4 count drops below 200 cells/mm³ or when certain AIDS-defining illnesses develop.

It's important to note that with effective antiretroviral therapy (ART), many people with HIV never progress to AIDS.
Starting inference for question (MedGemma-3-27B): How is HIV transmitted?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV is transmitted through specific bodily fluids: blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk.

Transmission typically occurs when these fluids from a person with HIV enter the bloodstream of an HIV-negative person. Common routes include unprotected sex (vaginal, anal, or oral), sharing needles or syringes, and from mother to child during pregnancy, childbirth, or breastfeeding.

It is important to note that HIV is *not* transmitted through casual contact like hugging, kissing, sharing utensils, or using the same toilet.
Starting inference for question (MedGemma-3-27B): What comorbidities are common among people living 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down common comorbidities in people living with HIV.

People living with HIV (PLWH) are at increased risk for several conditions, often due to chronic inflammation, immune dysregulation, and the effects of the virus itself, even when well-controlled on antiretroviral therapy (ART).

**Common comorbidities include:**

1.  **Cardiovascular Disease:** Heart attack, stroke, peripheral vascular disease.
2.  **Kidney Disease:** Chronic kidney disease, HIV-associated nephropathy.
3.  **Liver Disease:** Hepatitis B or C co-infection, fatty liver disease, cirrhosis.
4.  **Certain Cancers:** Kaposi's sarcoma, non-Hodgkin lymphoma, cervical cancer, anal cancer, lung cancer.
5.  **Neurological Conditions:** Neurocognitive impairment (HIV-associated neurocognitive disorders or HAND), peripheral neuropathy.
6.  **Bone Disease:** Osteoporosis, osteopenia.
7.  **Mental Health Conditions:** Depression, anxiety, substance use disorders.
8.  **Infectious Diseases:** Tuberculosis, pneumonia, opportunistic infections (especially if HIV is not well-controlled).

It's crucial to screen for and manage these conditions proactively in all PLWH.
Starting inference for question (MedGemma-3-27B): How can HIV be prevented?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down HIV prevention. Here are the key strategies:

1.  **Condom Use:** Consistent and correct use of latex or polyurethane condoms significantly reduces the risk of transmission during sexual activity.
2.  **Pre-Exposure Prophylaxis (PrEP):** Daily medication (usually a combination of tenofovir disoproxil fumarate and emtricitabine) taken by HIV-negative individuals at high risk can prevent infection.
3.  **Post-Exposure Prophylaxis (PEP):** Antiretroviral medications taken within 72 hours of a potential exposure can prevent infection.
4.  **Treatment as Prevention (TasP):** People with HIV who achieve and maintain an undetectable viral load on antiretroviral therapy cannot sexually transmit the virus to others (Undetectable = Untransmittable, or U=U).
5.  **Harm Reduction:** For people who inject drugs, using sterile needles and syringes prevents HIV transmission. Needle exchange programs are crucial.
6.  **Voluntary Medical Male Circumcision (VMMC):** Circumcision reduces the risk of female-to-male sexual transmission in high-prevalence settings.
7.  **Testing and Counseling:** Regular HIV testing allows for early diagnosis and linkage to care, preventing further transmission. Counseling helps individuals understand their risk and prevention options.
8.  **Prevention of Mother-to-Child Transmission (PMTCT):** Antiretroviral therapy for pregnant individuals with HIV drastically reduces the risk of transmission to their infants during pregnancy, labor, and breastfeeding.

These are the main evidence-based methods. Let me know if you'd like more detail on any specific one.
Starting inference for question (MedGemma-3-27B): How frequently ART must be taken?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): For most people living with HIV, antiretroviral therapy (ART) must be taken **every day**, usually once daily.

Consistency is crucial for ART to be effective. Missing doses can lead to drug resistance and treatment failure.
Starting inference for question (MedGemma-3-27B): How can we prevent Perinatal transmission of HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down how we prevent perinatal HIV transmission. It's a multi-pronged approach, focusing on the mother, the baby, and the delivery process.

1.  **Antiretroviral Therapy (ART) for the Mother:** This is the most crucial step. Starting ART as early as possible during pregnancy, continuing through pregnancy, delivery, and postpartum, dramatically reduces the viral load, often to undetectable levels. This significantly lowers the risk of transmission.
2.  **Antiretroviral Prophylaxis for the Infant:** The baby receives ART medication shortly after birth and continues for several weeks (typically 4-6 weeks, sometimes longer depending on risk factors).
3.  **Mode of Delivery:** Cesarean section (C-section) before labor begins and before rupture of membranes is recommended for women with a detectable viral load near delivery to further reduce transmission risk. For women with undetectable viral loads, vaginal delivery is generally considered safe.
4.  **Infant Feeding:** In high-income settings where safe alternatives are available, formula feeding is recommended to eliminate the risk of transmission through breast milk. In resource-limited settings, the benefits of breastfeeding may outweigh the risks, and exclusive breastfeeding for a shorter duration (e.g., 6 months) while the mother is on ART might be recommended, along with careful counseling.
5.  **Maternal Viral Load Monitoring:** Regularly monitoring the mother's viral load throughout pregnancy is essential to ensure ART is effective and to guide delivery decisions.

Essentially, the goal is to keep the mother's viral load as low as possible, protect the infant with medication, and choose the safest delivery method based on viral load status.
Starting inference for question (MedGemma-3-27B): What are the main cell types infected with HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV primarily infects cells that express the CD4 receptor and a coreceptor (usually CCR5 or CXCR4) on their surface.

The main cell types infected are:
1.  **CD4+ T lymphocytes (T helper cells):** These are the primary target and their depletion is a hallmark of HIV infection, leading to immunodeficiency.
2.  **Macrophages:** These phagocytic cells are also infected and can act as a reservoir for the virus.
3.  **Dendritic cells:** These antigen-presenting cells can be infected and facilitate viral transmission.

Other cells like microglia in the brain and certain epithelial cells can also be infected, but to a lesser extent.
Starting inference for question (MedGemma-3-27B): What is the difference between HIV and AIDS?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): That's a great question to start with.

HIV (Human Immunodeficiency Virus) is the virus itself. It attacks the immune system, specifically CD4 cells (T cells).

AIDS (Acquired Immunodeficiency Syndrome) is the most advanced stage of HIV infection. It's a syndrome, meaning a collection of symptoms and illnesses, that occurs when the immune system is severely damaged by HIV.

Essentially, you have HIV first, and if left untreated, it can progress to AIDS. With treatment, people with HIV can live long, healthy lives and may never develop AIDS.
Starting inference for question (MedGemma-3-27B): How is HIV not transmitted?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's clarify HIV transmission. HIV is *not* transmitted through:

*   **Air or water**
*   **Insects like mosquitoes or ticks**
*   **Saliva, sweat, tears, or urine** (unless visibly contaminated with blood)
*   **Casual contact** like hugging, shaking hands, sharing toilets, or sharing dishes.

Essentially, it requires direct contact with specific body fluids (blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, breast milk) from an infected person, typically through broken skin, mucous membranes, or direct injection.
Starting inference for question (MedGemma-3-27B): What is known about the switch that occurs between
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the switch from latent to active HIV infection.

**Key Points:**

1.  **Latency:** HIV can hide in a dormant state (latent) within certain immune cells, primarily CD4+ T cells. In this state, the virus isn't actively replicating and isn't detectable by standard tests.
2.  **Reactivation:** This latency isn't permanent. Various factors can trigger the virus to "wake up" and start replicating again (reactivation).
3.  **Triggers:** Common triggers for reactivation include:
    *   Immune system activation (e.g., due to other infections, inflammation)
    *   Certain medications (e.g., corticosteroids)
    *   Stress
    *   Changes in immune status (e.g., starting or stopping antiretroviral therapy - ART)
4.  **Mechanism:** The exact molecular switch isn't fully understood, but it involves changes in gene expression within the latently infected cell, allowing the virus to transition from a dormant to a replicative state.
5.  **Clinical Significance:** Reactivation can lead to increased viral load, potential damage to the immune system, and increased risk of transmission. This is why consistent ART is crucial – it suppresses viral replication and reduces the frequency and magnitude of reactivation events.

**In short:** Latent HIV isn't gone, just dormant. Various triggers can cause it to reactivate and start replicating, leading to active infection. Understanding these triggers and the mechanisms of reactivation is a major focus of HIV research.
Saved MedGemma-3-27B answers (category=1, iteration=1) to: /cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation/model_answers/raw/MedGemma-3-27B/MedGemma-3-27B_answers_category_1.1_HIV_EQ.json
Starting inference for question (MedGemma-3-27B): How is HIV diagnosed?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV is diagnosed using a combination of laboratory tests.

1.  **Antibody Tests:** These look for antibodies your immune system makes in response to HIV. They can be done using blood or oral fluid.
2.  **Antigen/Antibody Tests:** These look for both HIV antibodies and antigens (part of the virus itself). They can detect HIV earlier than antibody-only tests.
3.  **Nucleic Acid Tests (NAT):** These look for the virus's genetic material (RNA). They are the most expensive and usually reserved for specific situations, like confirming positive results or diagnosing acute infection.

Initial screening often uses an antibody or antigen/antibody test. If positive, confirmatory tests (like a different type of antibody test or a NAT) are performed.
Starting inference for question (MedGemma-3-27B): What are the different stages of HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the stages of HIV infection. It's typically described in three main stages:

1.  **Acute HIV Infection:** This is the earliest stage, occurring within 2 to 4 weeks after infection. The virus is multiplying rapidly, and the immune system is starting to respond. Many people experience flu-like symptoms (fever, chills, rash, night sweats, muscle aches, sore throat, fatigue, swollen lymph nodes, mouth ulcers). Viral load is very high during this stage, making transmission risk high.
2.  **Chronic HIV Infection (Clinical Latency):** This stage can last for many years (a decade or more without treatment). The virus is still active but reproduces at low levels. People may not have any symptoms, or only mild ones. However, the virus is still damaging the immune system. With treatment (ART), people can stay in this stage for decades and may never progress to AIDS.
3.  **Acquired Immunodeficiency Syndrome (AIDS):** This is the most severe stage. It occurs when the immune system is badly damaged, usually indicated by a very low CD4 cell count (less than 200 cells/mm³) or the development of certain opportunistic infections or cancers. Without treatment, people with AIDS typically survive about 3 years.

It's important to remember that with early diagnosis and consistent antiretroviral therapy (ART), most people with HIV can live long, healthy lives and never reach the AIDS stage.
Starting inference for question (MedGemma-3-27B): How is HIV transmitted?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV is transmitted through specific bodily fluids:

1.  **Blood:** Sharing needles, accidental needlesticks, blood transfusions (rare in countries with screening).
2.  **Semen and Pre-seminal Fluid:** Unprotected sexual contact (anal, vaginal, or oral).
3.  **Rectal Fluids:** Unprotected anal sex.
4.  **Vaginal Fluids:** Unprotected vaginal sex.
5.  **Breast Milk:** From an HIV-positive mother to her child during breastfeeding.

It is **not** transmitted through casual contact like hugging, sharing utensils, or toilet seats.
Starting inference for question (MedGemma-3-27B): What comorbidities are common among people living 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, I can help with that. People living with HIV are at increased risk for several comorbidities, both related to the virus itself and its effects on the immune system, as well as non-HIV related conditions often associated with aging and lifestyle factors.

Common comorbidities include:

*   **Cardiovascular disease:** Heart attack, stroke, peripheral vascular disease.
*   **Kidney disease:** HIV-associated nephropathy (HIVAN), chronic kidney disease.
*   **Liver disease:** Hepatitis B or C co-infection, fatty liver disease, cirrhosis.
*   **Certain cancers:** Kaposi sarcoma, non-Hodgkin lymphoma, cervical cancer, anal cancer.
*   **Bone disease:** Osteoporosis, osteopenia.
*   **Neurological conditions:** Neurocognitive disorders (HIV-associated neurocognitive disorder or HAND).
*   **Mental health conditions:** Depression, anxiety, substance use disorders.
*   **Infectious diseases:** Tuberculosis, pneumonia, opportunistic infections (especially if HIV is not well-controlled).

It's important to remember that with effective antiretroviral therapy (ART), many people with HIV can live long, healthy lives, and the risk of some of these comorbidities can be significantly reduced. Regular screening and management of these conditions are crucial.
Starting inference for question (MedGemma-3-27B): How can HIV be prevented?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, I can help with that. HIV prevention involves several strategies:

1.  **Condom Use:** Consistent and correct use of latex or polyurethane condoms significantly reduces the risk of transmission during sexual activity.
2.  **Pre-Exposure Prophylaxis (PrEP):** Taking a daily medication (like Truvada or Descovy) can prevent HIV infection in people who are HIV-negative but at high risk.
3.  **Post-Exposure Prophylaxis (PEP):** Taking antiretroviral medications soon after a potential exposure (within 72 hours) can prevent HIV infection.
4.  **Testing and Treatment:** Regular HIV testing allows for early diagnosis. Treating HIV effectively with antiretroviral therapy (ART) reduces the viral load, often to undetectable levels, making transmission extremely unlikely (Undetectable = Untransmittable, U=U).
5.  **Harm Reduction for Injection Drug Users:** Using sterile needles and syringes and not sharing injection equipment prevents HIV transmission. Needle exchange programs can help.
6.  **Prevention of Mother-to-Child Transmission (PMTCT):** HIV-positive pregnant individuals taking ART can significantly reduce the risk of transmitting HIV to their baby.

These are the main, evidence-based methods. Do you have any specific questions about one of these?
Starting inference for question (MedGemma-3-27B): How frequently ART must be taken?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Antiretroviral therapy (ART) for HIV must be taken **every day**, as prescribed. Consistent daily adherence is crucial for effective viral suppression and preventing drug resistance.
Starting inference for question (MedGemma-3-27B): How can we prevent Perinatal transmission of HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, here's a breakdown of preventing perinatal HIV transmission:

1.  **Antiretroviral Therapy (ART):** The most crucial step. The pregnant person with HIV should be on effective ART throughout pregnancy, labor, and delivery. This significantly reduces the viral load, making transmission much less likely.
2.  **Infant Prophylaxis:** The newborn receives antiretroviral medication for several weeks after birth.
3.  **Delivery Method:** Cesarean section (C-section) may be recommended if the mother's viral load is high near delivery, though ART is the primary factor. Vaginal delivery is generally safe if the viral load is undetectable.
4.  **Feeding:** Avoid breastfeeding in settings where safe alternatives are available. Formula feeding eliminates the risk of transmission through breast milk.

These interventions, when implemented together, reduce the risk of transmission to less than 1%.
Starting inference for question (MedGemma-3-27B): What are the main cell types infected with HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): The main cell types infected by HIV are:

1.  **CD4+ T lymphocytes (T helper cells):** These are the primary targets. HIV binds to the CD4 receptor on their surface.
2.  **Macrophages:** These cells also express CD4, albeit at lower levels, and can be infected.
3.  **Dendritic cells:** These cells can also be infected, playing a role in viral transmission.

HIV primarily targets cells expressing the CD4 receptor and a coreceptor (usually CCR5 or CXCR4).
Starting inference for question (MedGemma-3-27B): What is the difference between HIV and AIDS?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's clarify the difference between HIV and AIDS.

**HIV** stands for Human Immunodeficiency Virus. It's a virus that attacks the body's immune system, specifically CD4 cells (T cells).

**AIDS** stands for Acquired Immunodeficiency Syndrome. It's *not* a virus itself, but rather a syndrome or a stage of HIV infection. It occurs when HIV has severely damaged the immune system, making the person vulnerable to opportunistic infections and certain cancers.

In short: **HIV is the virus, AIDS is the late stage of the infection caused by the virus.**

A person can have HIV without having AIDS. With proper treatment, many people with HIV never develop AIDS.
Starting inference for question (MedGemma-3-27B): How is HIV not transmitted?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV is *not* transmitted through casual contact. This includes:

*   **Air or water:** You cannot get HIV from breathing the same air or drinking from the same glass as someone with HIV.
*   **Insects:** Mosquitoes, ticks, or other insects cannot transmit HIV.
*   **Saliva, tears, sweat:** Kissing, sharing utensils, or contact with these bodily fluids does not transmit HIV unless there is blood present.
*   **Toilet seats, doorknobs:** HIV does not survive well outside the body and cannot be transmitted through inanimate objects.
*   **Sharing food or drinks:** HIV is not transmitted this way.
Starting inference for question (MedGemma-3-27B): What is known about the switch that occurs between
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the switch from latent HIV to active infection.

**Key Concepts:**

*   **Latent HIV:** The virus is dormant, hiding within certain immune cells (primarily resting CD4+ T cells). It's not actively replicating.
*   **Active Infection:** The virus is replicating, producing new virions, and causing damage to the immune system.

**The "Switch" Process:**

1.  **Activation Signal:** Something triggers the resting CD4+ T cell where latent HIV resides. This could be:
    *   Immune activation (e.g., response to another infection, inflammation).
    *   Cytokines (signaling molecules released by immune cells).
    *   Certain drugs (though this is less common clinically, it's relevant in research).
2.  **Viral Reactivation:** The activation signal tells the cell to "wake up." This includes turning on the HIV genes that were previously silenced.
3.  **Viral Replication:** The activated cell starts producing HIV RNA and proteins.
4.  **Virion Production & Spread:** New virus particles (virions) are assembled and released from the cell, ready to infect other CD4+ T cells.
5.  **Immune Response & Cell Death:** The newly active infection triggers an immune response. Often, the infected cell is eventually killed by cytotoxic T lymphocytes (CTLs) or undergoes apoptosis (programmed cell death).

**In essence:** It's a process of cellular activation leading to viral gene expression, replication, and ultimately, the production of new infectious virus. This reactivation is a major barrier to curing HIV, as these latent reservoirs can persist despite antiretroviral therapy (ART).
Saved MedGemma-3-27B answers (category=1, iteration=2) to: /cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation/model_answers/raw/MedGemma-3-27B/MedGemma-3-27B_answers_category_1.2_HIV_EQ.json
Starting inference for question (MedGemma-3-27B): How is HIV diagnosed?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV is diagnosed using a combination of laboratory tests.

1.  **Antibody Tests:** These look for antibodies your immune system makes in response to HIV. Examples include rapid tests (finger prick or oral fluid) and laboratory-based tests (blood draw).
2.  **Antigen/Antibody Tests:** These look for both HIV antibodies and a specific HIV antigen called p24. Antigen/antibody tests can detect HIV infection earlier than antibody-only tests.
3.  **Nucleic Acid Tests (NAT):** These look for the virus itself in the blood. NATs are typically used when there's a high suspicion of recent infection or to confirm positive results from other tests.

Often, a rapid antibody test is done first. If positive, it's confirmed with a more specific lab test like an antigen/antibody test or a NAT.
Starting inference for question (MedGemma-3-27B): What are the different stages of HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the stages of HIV infection. It's generally categorized into three main stages:

1.  **Acute HIV Infection:** This is the earliest stage, occurring within 2-4 weeks after infection. Symptoms can be flu-like (fever, chills, rash, night sweats, muscle aches, sore throat, fatigue, swollen lymph nodes, mouth ulcers). Viral load is very high, making transmission risk high.
2.  **Chronic HIV Infection (Clinical Latency):** The virus is still active but reproduces at low levels. People may not have symptoms or only mild ones. Without treatment, this stage can last for many years (average 10 years), but the virus gradually weakens the immune system. Viral load is lower than in the acute stage, but transmission is still possible.
3.  **Acquired Immunodeficiency Syndrome (AIDS):** This is the most severe stage. It occurs when the immune system is badly damaged, typically when the CD4 cell count drops below 200 cells/mm³ or when certain opportunistic infections or cancers develop. Symptoms are severe and include rapid weight loss, recurring fever, night sweats, swollen lymph nodes, chronic diarrhea, fatigue, sores of the mouth, throat, and genitals, pneumonia, neurological disorders, and certain cancers.

It's crucial to remember that with effective antiretroviral therapy (ART), people with HIV can stay in the chronic stage for decades and never progress to AIDS. ART can also reduce the viral load to undetectable levels, preventing transmission to others (Undetectable = Untransmittable, U=U).
Starting inference for question (MedGemma-3-27B): How is HIV transmitted?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV is transmitted through specific bodily fluids: blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk.

Transmission occurs when these fluids from a person with HIV enter the body of someone who doesn't have HIV. This can happen through:

*   **Sexual contact:** Anal, vaginal, or oral sex with someone who has HIV.
*   **Sharing needles or syringes:** Primarily for injection drug use.
*   **Mother-to-child:** During pregnancy, childbirth, or breastfeeding.
*   **Accidental needlestick injuries:** In healthcare settings.
*   **Blood transfusions or organ transplants:** (Rare in countries with effective screening).

It's important to note that HIV is **not** transmitted through casual contact like hugging, sharing utensils, or using the same toilet.
Starting inference for question (MedGemma-3-27B): What comorbidities are common among people living 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Common comorbidities in people living with HIV include:

*   **Cardiovascular disease:** Heart attack, stroke, heart failure.
*   **Kidney disease:** Chronic kidney disease, end-stage renal disease.
*   **Liver disease:** Hepatitis B or C coinfection, fatty liver disease, cirrhosis.
*   **Bone disease:** Osteoporosis, osteopenia.
*   **Neurological disorders:** Neurocognitive impairment, peripheral neuropathy.
*   **Cancers:** Certain cancers like Kaposi sarcoma, non-Hodgkin lymphoma, anal cancer, cervical cancer.
*   **Mental health conditions:** Depression, anxiety, substance use disorders.
*   **Infectious diseases:** Tuberculosis, pneumonia, opportunistic infections (especially if HIV is poorly controlled).
Starting inference for question (MedGemma-3-27B): How can HIV be prevented?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV prevention involves several strategies:

1.  **Condom Use:** Consistent and correct use of latex or polyurethane condoms significantly reduces transmission risk during vaginal, anal, or oral sex.
2.  **PrEP (Pre-Exposure Prophylaxis):** Taking a daily pill (or receiving long-acting injections) can prevent HIV infection in people who are HIV-negative but at high risk.
3.  **PEP (Post-Exposure Prophylaxis):** Taking HIV medication within 72 hours of a potential exposure can prevent infection.
4.  **Treatment as Prevention (TasP):** People with HIV who take their antiretroviral therapy (ART) as prescribed and achieve an undetectable viral load cannot sexually transmit HIV to others (Undetectable = Untransmittable, U=U).
5.  **Needle Exchange Programs:** Providing sterile needles reduces HIV transmission among people who inject drugs.
6.  **Testing and Counseling:** Regular HIV testing allows for early diagnosis and linkage to care, preventing further transmission.
7.  **Preventing Mother-to-Child Transmission:** HIV-positive pregnant individuals taking ART can significantly reduce the risk of transmitting HIV to their baby.
8.  **Voluntary Medical Male Circumcision:** Circumcision can reduce the risk of female-to-male sexual transmission in high-prevalence areas.
Starting inference for question (MedGemma-3-27B): How frequently ART must be taken?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's address this question about ART frequency.

Antiretroviral therapy (ART) for HIV needs to be taken **every day**, without missing doses.

Consistency is crucial for the medication to work effectively, suppress the virus, and prevent the development of drug resistance.
Starting inference for question (MedGemma-3-27B): How can we prevent Perinatal transmission of HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the key strategies for preventing perinatal HIV transmission (mother-to-child transmission, or MTCT).

1.  **Antiretroviral Therapy (ART) for the Mother:** This is the most critical step. The mother should be on effective ART throughout pregnancy, labor, and delivery, and ideally continue it long-term for her own health. The goal is to achieve and maintain an undetectable viral load.
2.  **Antiretroviral Prophylaxis for the Infant:** The newborn receives HIV medication for a period after birth (usually 4-6 weeks, sometimes longer depending on risk factors).
3.  **Mode of Delivery:** Cesarean section (C-section) is often recommended if the mother's viral load is not suppressed near delivery, to reduce the infant's exposure during birth. Vaginal delivery is generally safe if the viral load is undetectable.
4.  **Infant Feeding:** In settings where safe alternatives are available, formula feeding is recommended to eliminate the risk of transmission through breast milk. If breastfeeding is necessary or chosen, the mother must be on effective ART with viral suppression, and the infant should receive prophylaxis.
5.  **Early Diagnosis and Treatment of HIV in the Infant:** Testing the infant for HIV early and starting treatment immediately if positive is crucial.

These combined strategies have dramatically reduced MTCT rates.
Starting inference for question (MedGemma-3-27B): What are the main cell types infected with HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV primarily infects cells that express the CD4 receptor and a coreceptor (usually CCR5 or CXCR4) on their surface.

The main cell types infected are:

1.  **CD4+ T lymphocytes (T helper cells):** These are the primary target cells. Their depletion is a hallmark of HIV infection and leads to immunodeficiency.
2.  **Macrophages:** These cells can also be infected and serve as a reservoir for the virus.
3.  **Dendritic cells:** These cells can capture the virus and transmit it to T cells.

Other cells like microglia (in the brain) and certain epithelial cells can also be infected, but to a lesser extent.
Starting inference for question (MedGemma-3-27B): What is the difference between HIV and AIDS?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): That's a fundamental question. Here's the key difference:

*   **HIV (Human Immunodeficiency Virus)** is the *virus* itself. It attacks the immune system, specifically CD4 cells (T cells).
*   **AIDS (Acquired Immunodeficiency Syndrome)** is the *late stage* of HIV infection. It's a syndrome, meaning a collection of symptoms and illnesses, that occurs when the immune system is severely damaged by HIV.

Essentially, you can have HIV without having AIDS, but you cannot have AIDS without having HIV. AIDS is diagnosed when the CD4 count drops below a certain level (typically 200 cells/mm³) or when specific opportunistic infections develop.
Starting inference for question (MedGemma-3-27B): How is HIV not transmitted?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV is **not** transmitted through:

*   **Casual contact:** Shaking hands, hugging, sharing toilets, sharing dishes/utensils.
*   **Air or water:** Coughing, sneezing, swimming pools.
*   **Insects:** Mosquitoes, ticks.
*   **Saliva, tears, or sweat:** Unless visibly mixed with blood.

Transmission requires direct contact with specific body fluids (blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, breast milk) from an HIV-positive person, entering the bloodstream of an HIV-negative person.
Starting inference for question (MedGemma-3-27B): What is known about the switch that occurs between
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the switch between latent and active HIV infection.

**Key Concepts:**

1.  **Latent Reservoir:** HIV can hide in a dormant state within certain immune cells (primarily resting CD4+ T cells, but also macrophages and monocytes). This is called the latent reservoir. In this state, the virus isn't actively replicating and isn't targeted by the immune system or antiretroviral therapy (ART).
2.  **Active Infection:** This is when the virus is actively replicating, producing new virions, and causing immune system damage. This is the state targeted by ART.
3.  **The "Switch" (Viral Reactivation):** This is the process where latent HIV becomes active again. It's not a simple on/off switch, but rather a complex process.

**What triggers reactivation?**

*   **Immune Activation:** Strong immune stimulation (e.g., from other infections, inflammation, certain cancers) is a major trigger. When immune cells become activated, the latent virus can also be activated.
*   **Cytokines:** Specific signaling molecules (cytokines) like IL-15, TNF-alpha, and IL-7 can stimulate HIV reactivation.
*   **Cellular Factors:** Certain cellular processes and transcription factors within the infected cell can influence reactivation.
*   **ART Interruption:** Stopping ART allows the virus to replicate freely, but it can also potentially lead to reactivation of latent virus.

**Why is this important?**

*   **Viral Persistence:** The latent reservoir is the main barrier to curing HIV. Even with effective ART suppressing active replication, the latent virus remains.
*   **Rebound:** If ART is stopped, the reactivated latent virus can quickly lead to a rapid increase in viral load and disease progression.
*   **Therapeutic Target:** Understanding the reactivation process is crucial for developing strategies (like "shock and kill") aimed at eliminating the latent reservoir.

**In short:** Reactivation occurs when stimuli (often immune-related) cause the latent virus within resting cells to start replicating again. This process is complex and involves multiple cellular and molecular factors. It's a major hurdle in achieving an HIV cure.
Saved MedGemma-3-27B answers (category=1, iteration=3) to: /cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation/model_answers/raw/MedGemma-3-27B/MedGemma-3-27B_answers_category_1.3_HIV_EQ.json
Starting inference for question (MedGemma-3-27B): How is HIV diagnosed?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV diagnosis typically involves a combination of approaches:

1.  **Antibody Tests:** These look for antibodies your immune system makes in response to HIV. They can be done via blood draw or oral fluid. Rapid antibody tests provide results in about 30 minutes.
2.  **Antigen/Antibody Tests (4th Generation Tests):** These look for both HIV antibodies and p24 antigen (a part of the virus itself). They can detect HIV earlier than antibody-only tests. These are usually done via blood draw.
3.  **Nucleic Acid Tests (NAT):** These look for the actual virus's genetic material (RNA) in the blood. They are the most expensive and usually reserved for specific situations, like confirming positive results from other tests or diagnosing acute HIV infection.

A positive result on an initial screening test is always confirmed with a second, different type of test.
Starting inference for question (MedGemma-3-27B): What are the different stages of HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the stages of HIV infection. It's typically described in three main stages:

1.  **Acute HIV Infection:** This is the earliest stage, occurring within 2-4 weeks after infection. The virus is multiplying rapidly, and the immune system is trying to fight it off. Many people experience flu-like symptoms (fever, rash, fatigue, swollen lymph nodes), but some have no symptoms. Viral load is very high during this stage, making transmission risk high.
2.  **Chronic HIV Infection (Clinical Latency):** The virus is still active but reproduces at lower levels. People may not have symptoms for many years, but the virus continues to damage the immune system. Without treatment, this stage can last for a decade or more, but eventually progresses to AIDS. With effective antiretroviral therapy (ART), people can stay in this stage for many years, potentially for life, with a very low or undetectable viral load.
3.  **Acquired Immunodeficiency Syndrome (AIDS):** This is the most severe stage. It occurs when the immune system is badly damaged, typically when the CD4 cell count drops below 200 cells/mm³ or when certain opportunistic infections or cancers develop. Without treatment, people with AIDS typically survive about 3 years.

It's important to remember that with early diagnosis and consistent ART, many people with HIV never progress to AIDS and can live long, healthy lives.
Starting inference for question (MedGemma-3-27B): How is HIV transmitted?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV is transmitted through specific bodily fluids: blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk.

Transmission occurs when these fluids from a person with HIV enter the bloodstream of an HIV-negative person. This typically happens through:

*   **Sexual contact:** Anal, vaginal, or oral sex with someone who has HIV.
*   **Sharing needles or syringes:** Primarily for injection drug use, but also for tattoos or piercings if equipment isn't sterile.
*   **Mother-to-child transmission:** During pregnancy, childbirth, or breastfeeding.
*   **Accidental needlesticks:** In healthcare settings.
*   **Blood transfusions/organ transplants:** Rare in countries with effective screening.

It is **not** transmitted through casual contact like hugging, sharing utensils, or using the same toilet.
Starting inference for question (MedGemma-3-27B): What comorbidities are common among people living 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, I can help with that. Here are some common comorbidities seen in people living with HIV:

*   **Cardiovascular disease:** Heart attack, stroke, high blood pressure.
*   **Kidney disease:** Chronic kidney disease, kidney failure.
*   **Liver disease:** Hepatitis B or C co-infection, fatty liver disease, cirrhosis.
*   **Certain cancers:** Kaposi's sarcoma, non-Hodgkin lymphoma, cervical cancer, anal cancer.
*   **Bone disease:** Osteoporosis, osteopenia.
*   **Neurological conditions:** Cognitive impairment, peripheral neuropathy.
*   **Mental health conditions:** Depression, anxiety, substance use disorders.
*   **Lung disease:** COPD, pneumonia.

These are often linked to chronic inflammation associated with HIV, aging, and lifestyle factors. It's important to screen for these conditions regularly.
Starting inference for question (MedGemma-3-27B): How can HIV be prevented?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down HIV prevention. Here are the key strategies:

1.  **Consistent and Correct Condom Use:** Using latex or polyurethane condoms every time during vaginal, anal, or oral sex significantly reduces transmission risk.
2.  **Pre-Exposure Prophylaxis (PrEP):** Taking a daily medication (or an injection) can drastically lower the risk of HIV infection for people who are HIV-negative but at high risk.
3.  **Post-Exposure Prophylaxis (PEP):** Taking antiretroviral medications within 72 hours after a potential exposure can prevent HIV infection.
4.  **Treatment as Prevention (TasP):** People with HIV who take their antiretroviral therapy (ART) daily as prescribed can achieve and maintain an undetectable viral load. When undetectable, they have effectively no risk of sexually transmitting HIV to an HIV-negative partner (Undetectable = Untransmittable, or U=U).
5.  **Avoiding Sharing Needles/Syringes:** Never share injection equipment (needles, syringes, cookers, cotton, water). Use sterile equipment every time.
6.  **Testing and Counseling:** Regular HIV testing helps people know their status. Counseling provides information on risk reduction.
7.  **Voluntary Medical Male Circumcision (VMMC):** Circumcision can reduce the risk of female-to-male sexual transmission in high-prevalence areas.
8.  **Prevention of Mother-to-Child Transmission (PMTCT):** HIV-positive pregnant people taking ART can significantly reduce the risk of transmitting HIV to their baby.

These are the main evidence-based methods. Do you have any specific questions about any of these?
Starting inference for question (MedGemma-3-27B): How frequently ART must be taken?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Antiretroviral therapy (ART) for HIV must be taken **every day**, consistently, as prescribed. Missing doses can lead to treatment failure and drug resistance.
Starting inference for question (MedGemma-3-27B): How can we prevent Perinatal transmission of HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the key strategies for preventing perinatal HIV transmission. It's a multi-pronged approach.

1.  **Antiretroviral Therapy (ART) for the Mother:** This is the most crucial step. Starting ART as early as possible during pregnancy and continuing it throughout pregnancy, labor, and delivery dramatically reduces the viral load, minimizing the risk of transmission. The goal is to achieve and maintain an undetectable viral load.
2.  **Antiretroviral Prophylaxis for the Infant:** The newborn receives ART for a specific period (usually 4-6 weeks) after birth to prevent infection if any virus was transmitted during delivery.
3.  **Mode of Delivery:** Cesarean section (C-section) before labor begins and before rupture of membranes is recommended for mothers with a detectable viral load near the time of delivery. Vaginal delivery is generally safe if the mother has an undetectable viral load.
4.  **Infant Feeding:** In resource-rich settings where safe alternatives are available, formula feeding is recommended to eliminate the risk of transmission through breast milk. In resource-limited settings, the benefits of breastfeeding may outweigh the risks if the mother is on effective ART with viral suppression.

These interventions, when implemented together, reduce the risk of perinatal transmission to less than 1%.
Starting inference for question (MedGemma-3-27B): What are the main cell types infected with HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV primarily infects cells that express the CD4 receptor and a coreceptor (usually CCR5 or CXCR4) on their surface.

The main cell types infected are:

1.  **CD4+ T lymphocytes (T helper cells):** These are the primary target and their depletion is a hallmark of HIV infection leading to immunodeficiency.
2.  **Macrophages:** These cells can harbor the virus for long periods and act as a reservoir.
3.  **Dendritic cells:** These cells play a role in transmitting the virus to T cells.

Other cells like microglia in the brain, gastrointestinal cells, and certain B cells can also be infected, but to a lesser extent.
Starting inference for question (MedGemma-3-27B): What is the difference between HIV and AIDS?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): That's a fundamental question. Here's the key difference:

*   **HIV (Human Immunodeficiency Virus)** is the *virus* itself. It attacks the immune system, specifically CD4 cells (T cells).
*   **AIDS (Acquired Immunodeficiency Syndrome)** is the *late stage* of HIV infection. It's a syndrome, meaning a collection of symptoms and illnesses, that occurs when the immune system is severely damaged by HIV.

Someone can have HIV without having AIDS. AIDS is diagnosed when the CD4 count drops below a certain level (usually 200 cells/mm³) or when specific opportunistic infections develop.
Starting inference for question (MedGemma-3-27B): How is HIV not transmitted?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's clarify HIV transmission. HIV is *not* transmitted through:

*   **Casual contact:** Shaking hands, hugging, sharing toilets, sharing dishes, or kissing (closed-mouth).
*   **Air or water:** It doesn't spread through coughing, sneezing, or swimming pools.
*   **Insects:** Mosquitoes, ticks, or other insects do not transmit HIV.
*   **Saliva, tears, or sweat:** Unless these fluids contain visible blood.

HIV is primarily transmitted through specific bodily fluids: blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk. Transmission requires these fluids to come into contact with a mucous membrane, damaged tissue, or be directly injected into the bloodstream.
Starting inference for question (MedGemma-3-27B): What is known about the switch that occurs between
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the switch from latent HIV to active infection.

**Key Concepts:**

*   **Latent HIV:** The virus is dormant, hiding in resting immune cells (mostly CD4+ T cells). It's not actively replicating or causing damage. Antiretroviral therapy (ART) can suppress active virus but *cannot* eliminate the latent reservoir.
*   **Active Infection:** The virus is actively replicating, destroying CD4+ T cells, and causing disease progression if untreated.

**The "Switch" (Viral Reactivation):**

*   **What it is:** The process where latent HIV "wakes up" and starts replicating again.
*   **Triggers:** Various factors can trigger reactivation, including:
    *   Immune stimulation (e.g., other infections, inflammation)
    *   Certain medications (e.g., corticosteroids)
    *   Stress
    *   Changes in immune status (e.g., stopping ART)
*   **Mechanism:** The exact molecular mechanisms are complex and still being researched, but involve signaling pathways within the host cell that alter the expression of viral genes, allowing transcription and replication to begin.
*   **Clinical Significance:** Reactivation can lead to:
    *   Increased viral load
    *   Decline in CD4+ T cell count
    *   Increased risk of HIV-related complications
    *   Potential for disease progression if ART is stopped or ineffective.

**In Summary:** The switch is viral reactivation, triggered by various stimuli, where dormant HIV begins replicating again. This is a major hurdle in achieving a complete cure for HIV.
Saved MedGemma-3-27B answers (category=1, iteration=4) to: /cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation/model_answers/raw/MedGemma-3-27B/MedGemma-3-27B_answers_category_1.4_HIV_EQ.json
Starting inference for question (MedGemma-3-27B): How is HIV diagnosed?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV diagnosis typically involves a combination of steps:

1.  **Risk Assessment:** Identifying potential exposure risks.
2.  **Antibody Test:** Detecting antibodies the body produces in response to HIV. This is the most common initial test.
3.  **Antigen/Antibody Test:** Detecting both HIV antibodies and p24 antigen (a protein part of the virus). This can detect infection earlier than antibody-only tests.
4.  **Nucleic Acid Test (NAT):** Detecting the actual virus's genetic material (RNA). This is used when a very early infection is suspected or to confirm positive results from other tests.

A positive result from an initial screening test is always confirmed with a second, different test.
Starting inference for question (MedGemma-3-27B): What are the different stages of HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the stages of HIV infection. It's typically described in three main stages:

1.  **Acute HIV Infection:** This is the earliest stage, occurring within 2-4 weeks after infection. Symptoms can be flu-like (fever, chills, rash, night sweats, muscle aches, sore throat, fatigue, swollen lymph nodes, mouth ulcers). The virus is multiplying rapidly and the viral load is very high, making transmission very likely.
2.  **Chronic HIV Infection (Clinical Latency):** In this stage, the virus is still active but reproduces at very low levels. People may not have any symptoms or only mild ones. Without treatment, this stage can last for many years (a decade or more), but the virus slowly damages the immune system. Towards the end of this stage, the viral load may increase, and the CD4 count may decrease, leading to more symptoms.
3.  **Acquired Immunodeficiency Syndrome (AIDS):** This is the most severe stage. It occurs when the immune system is badly damaged by HIV, leaving the person vulnerable to opportunistic infections and certain cancers. A diagnosis of AIDS is typically made when the CD4 cell count drops below 200 cells/mm³ or if the person develops certain AIDS-defining illnesses.

It's important to remember that with effective antiretroviral therapy (ART), people with HIV can stay in the chronic infection stage for many years, often living long and healthy lives, and may never progress to AIDS.
Starting inference for question (MedGemma-3-27B): How is HIV transmitted?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV is transmitted through specific bodily fluids from an infected person:

1.  **Blood:** Sharing needles, syringes, or other injection equipment; accidental needlesticks; blood transfusions (rare in countries with screening).
2.  **Semen and Pre-seminal fluid:** Through vaginal, anal, or oral sex.
3.  **Rectal fluids:** Through anal sex.
4.  **Vaginal fluids:** Through vaginal sex.
5.  **Breast milk:** From mother to child during breastfeeding.

It is **not** transmitted through casual contact like hugging, kissing, sharing utensils, or using the same toilet.
Starting inference for question (MedGemma-3-27B): What comorbidities are common among people living 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's go over common comorbidities in people living with HIV.

People with HIV are at increased risk for several conditions, including:

*   **Cardiovascular disease:** Heart attack, stroke, peripheral vascular disease.
*   **Kidney disease:** HIV-associated nephropathy (HIVAN), chronic kidney disease.
*   **Liver disease:** Hepatitis B or C co-infection, fatty liver disease, cirrhosis.
*   **Certain cancers:** Kaposi sarcoma, non-Hodgkin lymphoma, cervical cancer, anal cancer.
*   **Bone disease:** Osteoporosis, osteopenia.
*   **Neurological conditions:** Neurocognitive disorders, peripheral neuropathy.
*   **Mental health conditions:** Depression, anxiety, substance use disorders.
*   **Infectious diseases:** Tuberculosis, pneumonia, opportunistic infections (especially if CD4 count is low).

It's important to remember that effective antiretroviral therapy (ART) significantly reduces the risk of many of these comorbidities, but the risk often remains higher than in the general population. Regular screening and management are crucial.
Starting inference for question (MedGemma-3-27B): How can HIV be prevented?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV prevention involves several strategies:

1.  **Condom Use:** Consistent and correct use of latex or polyurethane condoms significantly reduces the risk of transmission during sexual contact.
2.  **PrEP (Pre-Exposure Prophylaxis):** Taking a daily medication (usually a combination of tenofovir disoproxil fumarate and emtricitabine) can prevent HIV infection in individuals at high risk.
3.  **PEP (Post-Exposure Prophylaxis):** Taking antiretroviral medications within 72 hours of potential exposure can prevent HIV infection.
4.  **Treatment as Prevention (TasP):** People with HIV who take their antiretroviral therapy (ART) daily as prescribed and achieve and maintain an undetectable viral load have effectively no risk of sexually transmitting HIV to an HIV-negative partner.
5.  **Harm Reduction:** For people who inject drugs, using sterile needles and syringes and not sharing equipment reduces the risk of HIV transmission.
6.  **Testing and Counseling:** Regular HIV testing allows for early diagnosis and linkage to care or prevention services. Counseling helps individuals understand their risk and how to reduce it.
7.  **Prevention of Mother-to-Child Transmission (PMTCT):** HIV-positive pregnant individuals taking ART can significantly reduce the risk of transmitting HIV to their baby.
Starting inference for question (MedGemma-3-27B): How frequently ART must be taken?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Adherence to Antiretroviral Therapy (ART) is crucial for effectiveness.

**Most ART regimens should be taken daily, once a day.**

There are some newer options, like long-acting injectables, that are given less frequently (e.g., every 1-2 months), but the standard is daily dosing.

It's vital for patients to take their medication exactly as prescribed to maintain viral suppression.
Starting inference for question (MedGemma-3-27B): How can we prevent Perinatal transmission of HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down how to prevent perinatal HIV transmission. It's a multi-pronged approach:

1.  **Antiretroviral Therapy (ART):** The mother takes ART throughout pregnancy, labor, and delivery. This is the most crucial step.
2.  **Infant Prophylaxis:** The baby receives ART (usually zidovudine or nevirapine) for the first 4-6 weeks after birth.
3.  **Delivery Mode:** Cesarean section is often recommended if the mother's viral load is high near delivery.
4.  **Infant Feeding:** Avoid breastfeeding if safe alternatives are available, as HIV can be transmitted through breast milk. Formula feeding is recommended in settings where it's safe and feasible.

Following these steps dramatically reduces the risk of transmission to less than 1%.
Starting inference for question (MedGemma-3-27B): What are the main cell types infected with HIV?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): HIV primarily infects cells that express the CD4 receptor and a coreceptor (usually CCR5 or CXCR4) on their surface. The most important of these are:

1.  **CD4+ T lymphocytes (T helper cells):** These are the main target cells and their depletion is a hallmark of HIV infection, leading to immunodeficiency.
2.  **Macrophages:** These cells also express CD4 and coreceptors and can be infected by HIV. They serve as a reservoir for the virus.
3.  **Dendritic cells:** These antigen-presenting cells can capture HIV and transmit it to T cells.

Other cells like microglia in the brain and certain epithelial cells can also be infected, but the above three are the most significant.
Starting inference for question (MedGemma-3-27B): What is the difference between HIV and AIDS?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): That's a fundamental question. Here's the difference:

*   **HIV (Human Immunodeficiency Virus)** is the virus itself. It attacks the immune system, specifically CD4 cells (T cells).
*   **AIDS (Acquired Immunodeficiency Syndrome)** is the most advanced stage of HIV infection. It's a syndrome, meaning a collection of symptoms and illnesses, that occurs when the immune system is severely damaged by HIV.

Essentially, you have HIV first. If left untreated, it can *progress* to AIDS. However, with treatment, people with HIV can live long, healthy lives and *never* develop AIDS.
Starting inference for question (MedGemma-3-27B): How is HIV not transmitted?
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's clarify how HIV is *not* transmitted. This is important for reducing stigma and unnecessary fear.

HIV is **not** spread through:

*   **Air or water**
*   **Saliva, tears, or sweat** (unless mixed with blood)
*   **Casual contact** like shaking hands, hugging, sharing toilets, or sharing dishes
*   **Mosquitoes or other insects**

Essentially, it's not transmitted through everyday interactions. Transmission requires direct contact with specific body fluids (blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, breast milk) from a person with HIV.
Starting inference for question (MedGemma-3-27B): What is known about the switch that occurs between
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down the switch from latent to active HIV infection.

**Key Concepts:**

*   **Latent HIV:** The virus is present in the body but is dormant or inactive. It's hiding in certain cells (mainly memory CD4+ T cells) and isn't replicating or causing damage. This is often called the "viral reservoir."
*   **Active HIV Infection:** The virus is actively replicating, destroying CD4+ T cells, and causing symptoms/disease progression.

**The "Switch":**

The switch from latent to active infection isn't a single event, but rather a process that can be triggered by various factors. Here's what we know:

1.  **Viral Reactivation:** The primary event is the reactivation of the latent virus within the reservoir cells. This means the virus starts replicating again.
2.  **Triggers:** Many things can trigger this reactivation, including:
    *   **Immune stimulation:** Other infections, inflammation, or even vaccinations can sometimes trigger reactivation.
    *   **Certain medications:** Some drugs can activate the virus.
    *   **Stress:** Physical or emotional stress might play a role.
    *   **Changes in immune status:** A decline in immune function can allow the virus to reactivate.
3.  **Viral Replication:** Once reactivated, the virus begins to replicate within the infected cells.
4.  **Spread:** The newly produced virus particles (virions) spread to infect new CD4+ T cells.
5.  **Immune Response:** The immune system tries to control the replicating virus, but often cannot completely eliminate it.
6.  **Viral Load Increase:** As the virus replicates and spreads, the amount of virus in the blood (viral load) increases.
7.  **Clinical Consequences:** If the viral load increases significantly, it can lead to a decline in CD4+ T cell counts, worsening symptoms, and progression of HIV disease.

**Important Note:** In people on effective Antiretroviral Therapy (ART), the goal is to suppress the virus to undetectable levels, preventing reactivation and maintaining immune function. However, the latent reservoir persists even with ART, which is why a cure is still challenging.

Does that clarify the process for you?
Saved MedGemma-3-27B answers (category=1, iteration=5) to: /cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation/model_answers/raw/MedGemma-3-27B/MedGemma-3-27B_answers_category_1.5_HIV_EQ.json
Starting inference for question (MedGemma-3-27B): A 58-year-old woman with HIV infection is brought 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): The user wants me to act as a senior HIV physician assisting a junior clinician. I need to provide a brief and clear answer to the question about the most likely diagnosis based on the clinical presentation and investigation results.

**Clinical Information:**
*   **Patient:** 58-year-old woman with HIV
*   **Symptoms:** 2-week history of headaches, blurred vision, confusion, ataxia, memory impairment.
*   **Medications:** ART, TMP-SMX (prophylaxis likely)
*   **CD4 count:** 90/μL (severe immunosuppression)
*   **CSF:** Lymphocytic pleocytosis, EBV DNA positive
*   **MRI:** Solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum.

**Differential Diagnosis for CNS lesions in HIV with low CD4:**
1.  **Primary CNS Lymphoma (PCNSL):** Common in advanced HIV. Often presents with neurological deficits, confusion, memory impairment. MRI typically shows solitary or multiple ring-enhancing lesions, often periventricular, sometimes involving the corpus callosum. CSF often shows high protein, sometimes pleocytosis (lymphocytic), and EBV DNA is frequently positive (highly suggestive).
2.  **Toxoplasmosis:** Most common opportunistic brain infection in HIV. Typically presents with multiple ring-enhancing lesions, often in the basal ganglia or corticomedullary junction. CSF may show pleocytosis, but EBV DNA is negative.
3.  **Progressive Multifocal Leukoencephalopathy (PML):** Caused by JC virus. Typically presents with focal neurological deficits, cognitive decline. MRI shows non-enhancing white matter lesions, often asymmetric, involving subcortical white matter. CSF is usually acellular or has mild lymphocytic pleocytosis; EBV DNA is negative.
4.  **Cryptococcoma:** Fungal infection. Can present as a solitary or multiple ring-enhancing lesion. CSF often shows pleocytosis and high opening pressure. India ink or cryptococcal antigen may be positive. EBV DNA is negative.
5.  **Tuberculoma:** Can present as a ring-enhancing lesion. CSF may show pleocytosis, high protein, low glucose. AFB stain/culture may be positive. EBV DNA is negative.
6.  **Other:** Abscess (bacterial/fungal), metastatic disease (less likely without known primary).

**Analysis of the Case:**
*   **Low CD4 count (90/μL):** High risk for opportunistic infections and malignancies.
*   **Symptoms:** Headaches, blurred vision, confusion, ataxia, memory impairment are consistent with a CNS mass lesion.
*   **CSF:** Lymphocytic pleocytosis is non-specific but can be seen in PCNSL, toxoplasmosis, cryptococcoma, etc. The **positive EBV DNA** is highly suggestive of PCNSL in this context.
*   **MRI:** **Solitary, weakly ring-enhancing lesion involving the corpus callosum** is a classic finding for PCNSL, although toxoplasmosis can sometimes present as a single lesion. However, the typical location for toxo is different (basal ganglia). The weak enhancement and well-defined borders can be seen in PCNSL.

**Conclusion:**
The combination of severe immunosuppression (CD4 90), neurological symptoms, CSF findings (lymphocytic pleocytosis, **positive EBV DNA**), and MRI findings (**solitary lesion involving the corpus callosum**) strongly points towards Primary CNS Lymphoma (PCNSL). While toxoplasmosis is common, the solitary lesion location, weak enhancement, and especially the positive EBV DNA make PCNSL the most likely diagnosis.<unused95>Based on the clinical presentation, CSF findings (lymphocytic pleocytosis and positive EBV DNA), and MRI results (solitary, weakly ring-enhancing lesion involving the corpus callosum) in a patient with advanced HIV (CD4 count 90/μL), the most likely diagnosis is **Primary CNS Lymphoma (PCNSL)**.

The positive EBV DNA in the CSF is highly suggestive of PCNSL in this setting. While toxoplasmosis is more common overall, it typically presents with multiple lesions, often in the basal ganglia, and is not associated with EBV DNA in the CSF.
Starting inference for question (MedGemma-3-27B): A 25-year-old sexually active male presents to an 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's address this question.

The class of antiretroviral medications that acts on the gp41 subunit of the HIV envelope glycoprotein is the **fusion inhibitors**.

Specifically, the drug **enfuvirtide** (Fuzeon) is the primary example of this class. It works by binding to gp41 and preventing the conformational changes needed for the viral and cellular membranes to fuse, thus blocking HIV entry into the host cell.
Starting inference for question (MedGemma-3-27B): A 27-year-old man presents with a 2-week history o
Device set to use cuda:0
Answer for question (MedGemma-3-27B): This patient is most likely in the **acute retroviral syndrome (ARS)** stage of HIV infection.

**Explanation:**

*   **Symptoms:** Fever, malaise, and diarrhea are common symptoms of ARS, which occurs 2-4 weeks after initial infection.
*   **Lymphadenopathy:** Enlarged lymph nodes (lymphadenopathy) are also characteristic of ARS.
*   **Positive HIV Test:** Confirms HIV infection.
*   **CD4 Count:** A CD4 count of 650/mm3 is within the normal range (typically >500/mm3) and is not indicative of advanced disease (AIDS). While CD4 counts can temporarily dip during ARS, they usually recover. The relatively high count suggests the infection is recent and hasn't significantly impacted the immune system yet.

ARS is the earliest symptomatic stage of HIV infection.
Starting inference for question (MedGemma-3-27B): A 50-year-old male with HIV presents to his primar
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Based on the clinical presentation (persistent fever, night sweats, productive cough), low CD4 count (85 cells/mm^3), and chest radiograph findings (cavitations), the patient likely has *Nocardia* pneumonia, an opportunistic infection in immunocompromised individuals. The bronchoalveolar lavage finding of partially acid-fast gram-positive branching rods is characteristic of *Nocardia*.

The most appropriate drug for managing *Nocardia* infection is **sulfonamides**, typically trimethoprim-sulfamethoxazole (TMP-SMX).

The mechanism of action of sulfonamides (like sulfamethoxazole) is the **inhibition of dihydropteroate synthase**, an enzyme essential for folic acid synthesis in bacteria. This blocks the conversion of PABA (para-aminobenzoic acid) to dihydrofolic acid, ultimately inhibiting bacterial growth.
Starting inference for question (MedGemma-3-27B): A physician scientist is looking for a more effici
Device set to use cuda:0
Answer for question (MedGemma-3-27B): 1.  **Identify the core question:** The question asks for the most likely target of a *new, potent antibody* being designed to fight HIV, given that natural antibodies target HIV envelope proteins.

2.  **Analyze the context:**
    *   HIV infects cells by binding to envelope proteins.
    *   The natural immune response produces antibodies against these envelope proteins.
    *   Diagnostic tests (ELISA, Western blot) detect these antibodies.
    *   The goal is a *new, more potent* antibody against the *same* envelope proteins.

3.  **Recall HIV envelope proteins:** The major HIV envelope proteins are gp120 and gp41.
    *   gp120 is the surface glycoprotein that binds to the CD4 receptor and co-receptors (CCR5 or CXCR4) on host cells. It's highly variable and exposed on the viral surface.
    *   gp41 is the transmembrane glycoprotein that mediates fusion of the viral envelope with the host cell membrane after gp120 binds. It's less exposed than gp120 but crucial for entry.

4.  **Consider the goal of a "more potent" antibody:**
    *   Potency often relates to blocking viral entry or neutralizing the virus.
    *   Antibodies targeting gp120 can block CD4/co-receptor binding, preventing entry.
    *   Antibodies targeting gp41 can block the conformational changes needed for fusion.
    *   Broadly neutralizing antibodies (bNAbs), which are highly potent, often target conserved regions of gp120 or gp41, or multiple epitopes simultaneously.

5.  **Evaluate the options (implicitly, as they aren't listed, but the question implies a choice):** The question asks *which* protein is the *most likely* target.
    *   **gp120:** This is the primary target for initial antibody binding and is involved in receptor attachment. It's a major target for neutralizing antibodies, especially bNAbs that target conserved regions or conformational epitopes. Its variability makes it challenging, but also a key area for potent antibody design.
    *   **gp41:** This protein is essential for membrane fusion. Antibodies targeting conserved regions of gp41 (like the HR1/HR2 region) can be potent fusion inhibitors.
    *   **Other envelope proteins?** There aren't other major, distinct envelope proteins commonly targeted in this way.

6.  **Synthesize and conclude:** Both gp120 and gp41 are targets of natural antibodies and potential targets for engineered antibodies. However, gp120 is the primary protein responsible for binding to host cells and is the major target for many potent neutralizing antibodies, including bNAbs which often target conserved epitopes on gp120 or conformational epitopes involving both gp120 and gp41. Given its central role in infection and its status as a major target for potent neutralizing antibodies, gp120 is arguably the *most likely* target for designing a *new, more potent* antibody aimed at blocking entry, while acknowledging gp41 is also a valid target. Since the question doesn't provide specific options, I should state the primary targets.

7.  **Refine the answer for clarity and brevity:** The key envelope proteins are gp120 and gp41. gp120 mediates attachment to host cells, and gp41 mediates fusion. Both are targets for antibodies. Potent neutralizing antibodies often target conserved regions of gp120 or conformational epitopes involving gp120 and gp41. Therefore, gp120 is a very likely target.<unused95>The main HIV envelope proteins targeted by the humoral immune response are **gp120** and **gp41**.

*   **gp120** is the surface protein responsible for binding to CD4 and co-receptors on host cells.
*   **gp41** is the transmembrane protein involved in membrane fusion.

Many potent, broadly neutralizing antibodies target conserved regions of gp120 or conformational epitopes involving both gp120 and gp41. Therefore, gp120 is a highly likely target for designing a more potent antibody.
Starting inference for question (MedGemma-3-27B): A 50-year-old HIV-positive male presents to the ER
Device set to use cuda:0
Answer for question (MedGemma-3-27B): That's a classic presentation. The biopsy finding of septate hyphae branching at acute angles is highly suggestive of *Aspergillus*.

Given the patient's HIV status and the fibrocavitary lesion, invasive pulmonary aspergillosis is the most likely diagnosis.

Let me know if you have any other questions.
Starting inference for question (MedGemma-3-27B): A 43-year-old man with HIV infection comes to the 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break this down.

The patient has HIV, is on ART (zidovudine, lamivudine, dolutegravir), and has CMV colitis causing diarrhea, weight loss, and bloody stools. He's being started on valganciclovir for the CMV.

The key here is the interaction between valganciclovir and zidovudine (AZT).

Valganciclovir is a prodrug of ganciclovir. Ganciclovir is primarily eliminated by the kidneys, but it can also cause bone marrow suppression (myelosuppression). Zidovudine (AZT) is also known to cause significant myelosuppression, particularly anemia and neutropenia.

Combining these two drugs significantly increases the risk of **myelosuppression**, specifically **anemia** and **neutropenia**.

Therefore, the patient is at greatest risk for **bone marrow suppression (anemia, neutropenia)**.
Starting inference for question (MedGemma-3-27B): A 28-year-old G1P0 woman at 16 weeks estimated ges
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break this down. The patient is HIV positive and wants to know how to test her baby for HIV right after birth.

The most appropriate diagnostic test to address this patient's concern is **HIV DNA PCR (polymerase chain reaction) testing** performed on the infant's blood.

Here's why:

*   **Sensitivity:** HIV DNA PCR is the most sensitive test for detecting HIV infection in infants younger than 18 months. It can detect the virus's genetic material even before antibodies develop.
*   **Timing:** It can be performed as early as 24-48 hours after birth, although results might be more reliable if done later (e.g., 1-2 weeks).
*   **Antibody Interference:** Maternal HIV antibodies cross the placenta, so antibody tests (like the standard HIV antibody test the mother had) will be positive in the infant for up to 18 months, even if the infant is not infected. PCR tests detect the virus itself, avoiding this issue.

While HIV RNA PCR is also used, DNA PCR is often preferred for initial diagnosis in newborns due to its high sensitivity. Antibody testing is not useful for diagnosing HIV infection in infants under 18 months due to maternal antibody transfer.
Starting inference for question (MedGemma-3-27B): A 32-year-old man comes to the office for a routin
Device set to use cuda:0
Answer for question (MedGemma-3-27B): This is a challenging ethical situation. Here's the most appropriate next step:

**Refuse the patient's request for confidentiality.**

Explain to the patient that while you respect his privacy, you have a duty to warn his wife about her potential exposure to HIV, especially since she is also your patient. This is based on the principle of beneficence and the legal/ethical obligation to protect third parties from serious harm. You must prioritize the health and safety of his wife. You should also discuss the legal implications of not disclosing in your jurisdiction.
Starting inference for question (MedGemma-3-27B): A 41-year-old woman presents with acute onset seve
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Based on the clinical presentation (acute severe epigastric pain radiating to the back, nausea, vomiting), elevated lipase and amylase, and CT findings (edematous pancreas, peripancreatic fluid), the patient most likely has acute pancreatitis.

The most common causes of acute pancreatitis are gallstones and alcohol use. However, this patient has a normal gallbladder on CT and reports only moderate alcohol use.

Given her history of HIV infection, especially if it is poorly controlled or if she is on certain antiretroviral medications, drug-induced pancreatitis should be considered. Some HIV medications, like didanosine (ddI), stavudine (d4T), and less commonly, abacavir or protease inhibitors, have been associated with pancreatitis.

Other potential causes to consider include hypertriglyceridemia (often associated with poorly controlled diabetes or HIV), hypercalcemia, or autoimmune pancreatitis, although these are less common.

Therefore, while the exact etiology isn't definitively known without further information (like her specific HIV medications, triglyceride levels, calcium levels, and viral load/CD4 count), **drug-induced pancreatitis related to her HIV medications is a strong possibility** given the exclusion of gallstones and moderate alcohol use. Further investigation into her HIV medications and other potential causes is warranted.
Starting inference for question (MedGemma-3-27B):  A 28-year-old primigravid woman at 38 weeks' gest
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break this down. The question asks about the biological process disrupted by zidovudine (AZT).

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI).

Therefore, it disrupts the **reverse transcription** process. HIV uses reverse transcriptase to convert its RNA genome into DNA, which is necessary for integrating into the host cell's DNA. Zidovudine inhibits this enzyme.
Starting inference for question (MedGemma-3-27B): What is known about DNA methylation profiles in pa
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down what we know about DNA methylation in the context of HIV-1 infection, both latent and active.

**Key Concepts:**

*   **DNA Methylation:** An epigenetic modification where a methyl group (CH3) is added to a DNA base (usually cytosine), often affecting gene expression. It's a key regulator of cellular processes.
*   **Latent HIV-1:** The virus is present in the body but is not actively replicating. It resides in a dormant state within certain cells (like CD4+ T cells).
*   **Active HIV-1 Infection:** The virus is actively replicating and causing damage to the immune system.

**What We Know:**

1.  **Host Cell Methylation Changes:** HIV infection, both active and latent, can alter the DNA methylation patterns of the *host* cells (primarily immune cells like CD4+ T cells).
    *   **Active Infection:** Often associated with *global hypomethylation* (overall decrease in methylation) and changes in methylation at specific gene promoters involved in immune function, inflammation, and cell cycle regulation.
    *   **Latent Infection:** The picture is more complex and less studied. Some studies suggest methylation patterns might be altered in latently infected cells compared to uninfected cells, potentially influencing the establishment or maintenance of latency. However, the specific changes and their functional significance are still being actively researched.

2.  **Proviral DNA Methylation:** The HIV-1 provirus (the viral DNA integrated into the host genome) itself can also be methylated.
    *   **Impact on Replication:** Methylation of the proviral DNA, particularly in certain regions like the LTR (Long Terminal Repeat), is generally associated with *reduced* viral gene expression and replication. This is thought to be one mechanism contributing to viral latency.
    *   **Variability:** The degree and location of proviral methylation can vary significantly between individuals and even within different cell types in the same individual.

**In Summary:**

*   HIV infection alters host cell DNA methylation, potentially impacting immune function and inflammation.
*   Methylation of the integrated HIV-1 provirus tends to suppress viral replication and is linked to latency.
*   The precise methylation profiles in latent vs. active infection are complex, dynamic, and still under investigation, but they play a role in viral persistence and host response.

This is a rapidly evolving field, and ongoing research continues to refine our understanding.
Saved MedGemma-3-27B answers (category=2, iteration=1) to: /cluster/home/gcardenal/HIV/medical_llm_evaluation/deploy_medical_llm_evaluation/model_answers/raw/MedGemma-3-27B/MedGemma-3-27B_answers_category_2.1_HIV_EQ.json
Starting inference for question (MedGemma-3-27B): A 58-year-old woman with HIV infection is brought 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): The user wants me to act as a senior HIV physician assisting a junior clinician.
The case involves a 58-year-old woman with HIV (CD4 = 90/μL), presenting with neurological symptoms (headache, blurred vision, confusion, ataxia, memory impairment).
CSF shows lymphocytic pleocytosis and EBV DNA+.
MRI shows a solitary, weakly ring-enhancing lesion in the corpus callosum.

Differential diagnoses for neurological symptoms in an HIV patient with low CD4 count include:
1.  **Toxoplasmosis:** Most common opportunistic infection causing brain lesions in HIV. Typically presents with multiple ring-enhancing lesions, often in the basal ganglia. CSF is usually non-specific but can show pleocytosis.
2.  **Primary CNS Lymphoma (PCNSL):** Often presents as a solitary, large, ring-enhancing lesion, frequently in the periventricular white matter or corpus callosum. CSF may show pleocytosis and elevated protein. EBV DNA is often positive in CSF in HIV-associated PCNSL.
3.  **Progressive Multifocal Leukoencephalopathy (PML):** Caused by JC virus. Typically presents with multiple white matter lesions, usually non-enhancing or minimally enhancing, often in subcortical white matter. CSF is usually non-specific.
4.  **Cryptococcosis:** Can cause meningitis or focal lesions (cryptococcomas). CSF typically shows pleocytosis, low glucose, high protein, and positive India ink or cryptococcal antigen. Lesions can enhance.
5.  **Tuberculoma:** Can cause focal lesions. CSF may show pleocytosis, low glucose, high protein, and positive AFB stain or PCR. Lesions are often ring-enhancing.
6.  **Syphilis (Neurosyphilis):** Can cause various neurological manifestations. CSF typically shows pleocytosis and elevated protein.
7.  **Other infections:** CMV, HSV, VZV, etc.
8.  **HIV Encephalopathy:** Diffuse brain atrophy, cognitive decline. MRI usually shows diffuse white matter changes.

Let's evaluate the given case:
*   **Patient Profile:** HIV+, low CD4 (90/μL), indicating significant immunosuppression.
*   **Symptoms:** Headache, blurred vision, confusion, ataxia, memory impairment - consistent with a space-occupying lesion or encephalitis.
*   **CSF:** Lymphocytic pleocytosis, EBV DNA+. EBV DNA in CSF is strongly associated with PCNSL in HIV patients.
*   **MRI:** Solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. This location (corpus callosum) and morphology (solitary, well-defined) are highly suggestive of PCNSL. While toxoplasmosis is more common overall, it typically presents with multiple lesions, often in the basal ganglia, and usually doesn't have EBV DNA in the CSF.

Considering the solitary lesion in the corpus callosum, the EBV DNA positivity in the CSF, and the patient's immunosuppressed state, Primary CNS Lymphoma (PCNSL) is the most likely diagnosis. Toxoplasmosis is less likely given the solitary nature and location of the lesion and the positive EBV PCR in CSF.

**Answer:** The most likely diagnosis is Primary CNS Lymphoma (PCNSL). The combination of a solitary, ring-enhancing lesion in the corpus callosum, lymphocytic pleocytosis in the CSF, and positive EBV DNA in the CSF strongly points towards this diagnosis in an immunocompromised patient.<unused95>Based on the clinical presentation, CSF findings, and MRI results, the most likely diagnosis is **Primary CNS Lymphoma (PCNSL)**.

Key points supporting this:
*   **Solitary lesion:** PCNSL often presents as a single lesion.
*   **Location:** The corpus callosum is a common site for PCNSL.
*   **EBV DNA in CSF:** This is highly suggestive of PCNSL in the context of HIV infection.
*   **Low CD4 count:** PCNSL typically occurs in patients with advanced immunosuppression (CD4 < 100/μL).
Starting inference for question (MedGemma-3-27B): A 25-year-old sexually active male presents to an 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): That's a good question regarding HIV treatment. The class of medications that targets the gp41 subunit of the HIV envelope glycoprotein is called **fusion inhibitors**.

An example of a fusion inhibitor is **enfuvirtide (Fuzeon)**. It works by binding to gp41 and preventing the conformational changes needed for the viral and cellular membranes to fuse, thus blocking HIV entry into the host cell.
Starting inference for question (MedGemma-3-27B): A 27-year-old man presents with a 2-week history o
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Based on the symptoms (fever, malaise, diarrhea, lymphadenopathy) and a positive HIV test, the patient is likely experiencing **acute retroviral syndrome (ARS)**, which occurs during the primary infection stage.

Despite the relatively high CD4 count (650/mm3), the clinical presentation is most consistent with ARS. ARS typically occurs 2-4 weeks after initial infection.
Starting inference for question (MedGemma-3-27B): A 50-year-old male with HIV presents to his primar
Device set to use cuda:0
Answer for question (MedGemma-3-27B): The user wants to know the mechanism of action of the most appropriate drug for a patient with HIV presenting with symptoms suggestive of an opportunistic infection.

1.  **Identify the likely diagnosis:**
    *   Patient profile: 50-year-old male, HIV positive, poorly adherent to HAART, low CD4 count (85 cells/mm³), persistent fevers, night sweats, productive cough.
    *   Imaging: Chest radiograph shows cavitations in upper and lower lobes.
    *   Microbiology: Bronchoalveolar lavage (BAL) shows partially acid-fast gram-positive branching rods.
    *   Differential diagnoses for cavitary lung lesions in an immunocompromised patient:
        *   Tuberculosis (TB): Usually acid-fast bacilli (AFB), often upper lobe cavitation. PPD is negative, but this doesn't rule out TB in HIV patients.
        *   Nocardiosis: Partially acid-fast, gram-positive branching rods. Can cause cavitary lesions, especially in immunocompromised individuals.
        *   Fungal infections (e.g., Aspergillosis, Histoplasmosis): Can cause cavitary lesions, but microbiology usually different.
        *   Bacterial pneumonia (e.g., Staph aureus, Klebsiella): Can cause cavitation, but microbiology usually different.
    *   The BAL result (partially acid-fast, gram-positive branching rods) strongly points towards **Nocardiosis**.

2.  **Identify the most appropriate drug for Nocardiosis:**
    *   The standard first-line treatment for Nocardiosis, especially pulmonary Nocardiosis, is **Trimethoprim-sulfamethoxazole (TMP-SMX)**.

3.  **Determine the mechanism of action of TMP-SMX:**
    *   TMP-SMX is a combination drug.
    *   **Trimethoprim (TMP):** Inhibits dihydrofolate reductase (DHFR), an enzyme essential for folate synthesis in bacteria.
    *   **Sulfamethoxazole (SMX):** Inhibits dihydropteroate synthase, another enzyme earlier in the bacterial folate synthesis pathway.
    *   The combination provides synergistic inhibition of folate synthesis, which is crucial for bacterial DNA and protein synthesis.

4.  **Formulate the answer:**
    *   State the likely diagnosis based on the clinical picture and BAL results (Nocardiosis).
    *   State the most appropriate drug (TMP-SMX).
    *   Explain the mechanism of action of TMP-SMX (synergistic inhibition of folate synthesis via DHFR and dihydropteroate synthase inhibition).
    *   Keep it brief and clear as requested.<unused95>Based on the clinical presentation, low CD4 count, and especially the bronchoalveolar lavage finding of partially acid-fast, gram-positive branching rods, the most likely diagnosis is pulmonary Nocardiosis.

The most appropriate drug for managing Nocardiosis is Trimethoprim-sulfamethoxazole (TMP-SMX).

The mechanism of action of TMP-SMX involves synergistic inhibition of bacterial folate synthesis. Trimethoprim inhibits dihydrofolate reductase, while sulfamethoxazole inhibits dihydropteroate synthase.
Starting inference for question (MedGemma-3-27B): A physician scientist is looking for a more effici
Device set to use cuda:0
Answer for question (MedGemma-3-27B): The user is asking for the most likely target of a potent neutralizing antibody against HIV, considering the natural humoral immune response targets envelope proteins.

1.  **Identify the core question:** Which HIV envelope protein is the most likely target for a potent neutralizing antibody?
2.  **Recall HIV structure and immune response:** HIV has an envelope composed of gp120 (surface) and gp41 (transmembrane). gp120 binds to CD4 and coreceptors (CCR5/CXCR4) on host cells, initiating entry. gp41 mediates membrane fusion.
3.  **Consider natural immune response:** The natural humoral response targets both gp120 and gp41. However, gp120 is highly variable and heavily glycosylated, making it difficult to generate broadly neutralizing antibodies (bnAbs) against it.
4.  **Consider potent neutralizing antibodies:** Potent neutralizing antibodies often target conserved regions essential for viral entry or fusion. While some bnAbs target gp120 (e.g., targeting the CD4 binding site or V3 loop), many highly potent bnAbs target conserved regions of gp41, particularly the pre-hairpin intermediate (pre-H) or the post-entry six-helix bundle (6-HB) formed during fusion. The 6-HB is a relatively conserved structure crucial for membrane fusion.
5.  **Evaluate the options (implicitly):** The question asks *which* protein is the *most likely* target. While gp120 is a target, its variability makes it less likely for a *potent* antibody compared to conserved regions of gp41.
6.  **Formulate the answer:** The gp41 protein, specifically conserved regions involved in membrane fusion like the 6-helix bundle, is a prime target for potent neutralizing antibodies because it is less variable than gp120 and essential for viral entry. Therefore, gp41 is the most likely target.<unused95>The gp41 protein is the most likely target.

While the natural immune response targets both gp120 and gp41, gp41 contains more conserved regions essential for membrane fusion, which are often targeted by potent neutralizing antibodies. Gp120 is highly variable, making it a more difficult target for broadly effective antibodies.
Starting inference for question (MedGemma-3-27B): A 50-year-old HIV-positive male presents to the ER
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Based on the clinical presentation (fever, hemoptysis, fibrocavitary lesion) and the biopsy findings (septate hyphae branching at acute angles), the most likely causal organism is *Aspergillus*.

*Aspergillus* species are common fungi that can cause invasive pulmonary aspergillosis in immunocompromised individuals, such as those with HIV. The characteristic microscopic finding of septate hyphae branching at acute angles (approximately 45 degrees) is highly suggestive of *Aspergillus*.
Starting inference for question (MedGemma-3-27B): A 43-year-old man with HIV infection comes to the 
Device set to use cuda:0
Answer for question (MedGemma-3-27B): Okay, let's break down this interaction.

The patient has HIV, is on ART (zidovudine, lamivudine, dolutegravir), and presents with diarrhea, weight loss, and bloody stools. Colonoscopy shows ulcers, and stool PCR is positive for CMV. He's started on valganciclovir for CMV colitis.

The question asks about the *greatest risk* of adverse effects from adding valganciclovir to his *current* ART regimen.

**Valganciclovir** is an antiviral used for CMV.
**Zidovudine (AZT)** is a nucleoside reverse transcriptase inhibitor (NRTI).

The key interaction here is between **valganciclovir** and **zidovudine (AZT)**. Both drugs can cause **myelosuppression** (bone marrow suppression), leading to anemia, neutropenia, and thrombocytopenia.

**Therefore, adding valganciclovir to zidovudine puts this patient at greatest risk for significant myelosuppression, particularly anemia and neutropenia.**

Keep monitoring his complete blood count (CBC) closely.
Starting inference for question (MedGemma-3-27B): A 28-year-old G1P0 woman at 16 weeks estimated ges
Device set to use cuda:0
Answer for question (MedGemma-3-27B): The user wants to know the most appropriate diagnostic test to determine if a baby born to an HIV-positive mother has contracted HIV.

1.  **Identify the core issue:** The patient is HIV-positive and concerned about vertical transmission to her newborn.
2.  **Consider the timing:** The question asks for a test "as soon as possible after delivery".
3.  **Evaluate common HIV tests in newborns:**
    *   **HIV antibody tests (like ELISA/rapid tests):** These are *not* appropriate immediately after birth because maternal antibodies can cross the placenta and remain in the baby's blood for up to 18 months, leading to false positives.
    *   **HIV DNA PCR (Polymerase Chain Reaction):** This test detects the virus's genetic material directly. It can be done relatively early (within the first few days/weeks of life) and is highly sensitive for detecting infection.
    *   **HIV RNA PCR (Polymerase Chain Reaction):** This test detects the virus's genetic material (RNA). It's also highly sensitive and can be done early, often even earlier than DNA PCR, but might be less widely available or more expensive.
    *   **HIV p24 antigen test:** Detects a viral protein. Less sensitive than PCR methods, especially early on.
4.  **Compare PCR methods:** Both DNA and RNA PCR are suitable for early infant diagnosis. DNA PCR is often preferred for routine screening due to availability and cost, although RNA PCR might be used in specific situations (e.g., very early testing).
5.  **Select the best option:** Given the need for early detection and the limitations of antibody tests, a virologic test like HIV DNA PCR or HIV RNA PCR is the most appropriate. DNA PCR is a standard and widely accepted method for this purpose.
6.  **Formulate the answer:** State that antibody tests are not suitable due to maternal antibodies. Recommend a virologic test, specifically mentioning HIV DNA PCR as a standard approach for early infant diagnosis. Keep it brief and clear.<unused95>Maternal HIV antibody tests are not appropriate for diagnosing HIV infection in the newborn because maternal antibodies can cross the placenta and persist in the infant's blood for up to 18 months, causing false positive results.

The most appropriate diagnostic test is a virologic test that detects the virus itself. **HIV DNA PCR** is the standard test used for early infant diagnosis, typically performed within the first few days to weeks after birth. HIV RNA PCR is also an option.
Starting inference for question (MedGemma-3-27B): A 32-year-old man comes to the office for a routin
Device set to use cuda:0
